var title_f3_25_3472="Short axis echo 1 HCM";
var content_f3_25_3472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/76594/shax1hcm_conv.mp4?title=Short+axis+echo+1+HCM\" style=\"width:360px;height:272px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parasternal short axis echocardiogram in a patient with hypertrophic cardiomyopathy (HCM)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Short axis view from a two-dimensional echocardiogram shows marked asymmetric hypertrophy of the posterior left ventricular wall and the papillary muscles. During systole, there is near obliteration of the left ventricular cavity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3472=[""].join("\n");
var outline_f3_25_3472=null;
var title_f3_25_3473="Diaphragmatic injury with left hemidiaphragm discontinuity";
var content_f3_25_3473=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diaphragmatic injury with left hemidiaphragm discontinuity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (axial imaging) demonstrates discontinuity of the posterior left hemidiaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3473=[""].join("\n");
var outline_f3_25_3473=null;
var title_f3_25_3474="Scleral buckle";
var content_f3_25_3474=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Scleral buckle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 238px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADuAecDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKMjOO9B4HNABRRSFgvJIHagBaKKRWDMwB5U4NAC0UUUAFFJkbsZ564o3D5ufu9fagBaKFO4AjoeagtruG5eZImy8LlJFIwVP+B7GgCeiooLiKdpVicM0T+W4H8LYBx+RFS0AFFFQw3UM0UMiP8spwmRjJwT/Q0ATUVT/tK1F3JbFz50bojDaeCwJXn3wana4jW7jtyT5siM6jHZSoP/oQoAlopnmp5/k5/ebd5HoM4/x/I04EEkA9OtAC0UUUAFFFNjdZEDIcqehoAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAATgZPSq0moWUf8ArLu3T/elUf1qado0hczlFix8xcgDHvmvPdbvPhXBM66v/wAIn5qna3mxQsQfTpQB217eotlJcWrrO0I80pGwJdR1A56kZx74qxY3dvf2cV1ZypNbyruR0OQRXki+Gfgprkh+yjw15jY4tL4QE56cI61atfhH4Rj3DQdd17TIWbf5Ona3Iqbj/Fgk8mgDu9Lv7m40q8hI26lYu0Tp1LbTlG+jrtOfc+lZnjzUWs/Dtv4gtH32ls8M1ygBPmW5kQsVA/iUDcPoR3rGtfhPb2l7Le2vi/xil5KgjeZtSDsyjoDlDnHbNJL8MtQGh3GkW3jnXlsZlZTHPHbzYDHJ+Yxhup9aAO/luEa3hvYXDwYDb1I2mNsfNn06H6CnRTA39zDyCiI+SeMHcP8A2WvN9M+HHibS9PnsbD4hXsdrMzMUfTYXCbuoTP3QSScDiltfhTebJV1Px74ruxJCIGEdwkAZBnAO1c45PfuaAPTyeCcZ+nes1NasftV1C95bqIFV2ZpFAVWHH8jXEr8G/DLRql9c69fIoxtudWnIP4BgKp/8IB8JNJkK3NloCSA5IvLsOePXe5oA2/C3j7w5d2t3cXXiPSVke7m2o92issauVTgnphc/jVK7+JfhQ+G7qWHxDpv2mYyBI/tChzliBxn0xTLWb4R6fGUt38FQqnPBts/n3qJvHHwkgQL/AGp4WC8ABEjOPyFAHQQ/EbweLWN38R6Yi7ATvnAxxWRN428NXVvc32meJNM+12s5cD7WqiaPqUOTyCOnoRVU+O/hHLGS2q+FivIw0cf8iKiPjD4OTkh77wi2P78MX9VoA1PCPjPQb3XL9LXW7SaO5ImQtKgx8q4HXryfyruYrmOdCbeeGU9BtYH+RryVtT+B1zMYy/g4v1yIo1/HOKlttJ+DWp7xaTeHMjqIb8RY/JxQB6hqV6bCzkuJYiyorMdjDPAJ749K4TwH4qtbqW2trwTWa2trHErXC4SSVwHbDdMgbR17mqkvwn8GavbSDRdQ1G2YqV8yx1aVwoII6FmGMZrD1XRvH3w50qebQ7m28XaJGC8lleW6pcqvXIZcB8e4NAHT6beCTxJqN2zCSK+voPKxzgRyGLPH0rsrZ1n8S3rD/l2gji/FiWP6BK8L8JajbahN4dl8N3QhuHSKSVXb93I5k3klfxYHGMY74rvNK8UifTpba4WXT9W1u+aOFjgoy5CF43xyAqHGec4oA7vSJxLa3GoSuvkzO0kbdhEBhTn0IG7/AIFTPDDyXGmfbZgQ95I1wAeyk4Qf98BapeKij2UOi2/7v7UFjbYB8kWQv4ZyB9AfSuhhjWGJI4xtRFCqPQCgAlkWKJ5JDhEBZj6AUqHcisQVyM4PUVzuoXa6vrqaNbM5itis986gFcfwxE+pOCfYe9ZfxO8U3ekW1povh2MXPijWGMFlED/qRg7rh/REHPueKALY12LxF4ivdB0t2aDTio1K4A+UMf8Algp7sf4vQcdTx1gGBgcCuN8A6Rb6PaR6TYzzyppzFry6bj7ZduCZGY45wWyeepA/hrsqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqpYXQvU+0QMrWjgeU4By/XLfTpj8+hFAFuiiigAooooAKKKKACiiigA69aikt4JQRJDG4PBDKDmo5btIblI5SAshCq3YN2U+hPb16dcZs0AcLr/AMMvBOpSo974b0zdLui3pbhcEjIPGOcj9a8n8TfCfwqutx2I0O30/UGH7iP7S8NvqCjr5cgPySj+6ePSvo+WNZY2SQZVuorlfEUOm31m2h+L7dJbO4wsVy6kRsf4cv8A8s5PTkZ7HtQB4o/w/wBDv9Ou7Hwt4i8UaF4ntIyY9IvdRZPnX+Fc8MDyAVJFc5f3/j7wP4dtvEuh+PLjV7Ay/Zrmy1FDI9vL/wA83DZwcgrkY7etev6/4e1XS9KFhr2nnxp4Zh+aN87dStAOhByPMwO4IbjvXjXw6h0fxR8eLZLC41S60K1PnLHqQy8sqKcb/XaemcnigD3D4K/EfUPGB1HSPFGlnS/EumhXmg2lVkib7rgHp71m/tHfEy98CaJZ2nh8xnWr4sQzDd5EQGC+31JIAzxWJ4W1lNS/a18QJayERw6SbWQDozI0f8j/ACrmvjBoun+Kvj7daPqOoR2bPo0Sws7hAXLk7fckUAcT4cWbxfrVuvjfxnqv2W+gNxH9nuGdVOcFWXOFIx0xXRah8JfB0Gl6hJZXE15dLFcvbzSykq7RBWAIGPvIW/KsS5+DXiLSLFZ9NmkgvI5W2wykBJXX/nm+f4hzzjPIp+iaL451GK+tEsLm1u4P3zRSIyDcVIIyRg5Geh70Ad38OfBPgWPTvCWr3GkWNzZ6vbmxuGnBcRXQ5QnPQthl+uK6Z/DfhWy+Gdtq0WiacJNOukFywt1LMI59jg8c5AJrxLwnaeMH8MarFb6Y9xp8MhW8gJPmJKpzvX0ccdPQU7RvEnjeWwutBgtUvI9UMkkMiLlZGPLEEcBgRkg96APpEeHPCOmeILe7OjaO+l6yipDIbVGRJsZAHGAHX9V961ZPBvg99Xngm0DRixhWTYbWMbeWBwMcV4Hp0/xA1zwq32Dw611pFwM+Wkq74ZFPzbecghhnHY1mWHib4k3GqiJ9GvvtiQm3y8DoGYdD069e9AHUa94W8Dx+L9DuzpunrZyeIJrKWBYxski8rC8DsHGfxq9428J/CjTPEyG+0i0jsDp8krLBK0Y3q45AB64Ncx4t+E/jqPRLS5upLJkt5BM0dsxZ1ldwMjjk/MT/AFq7/wAKQbW/ib/ZOra7qFxYWVglxcygAEuzELGp6Dpk0AeMajLpNrf3GpeG7y70BUzLaosrlmYH5VDDngY59a+tP2c/H9z8QvAkraziTU7CT7LcybcCYFcq5HqRkH3FcH8Rfg/4F8J6RJeT6sbZ+kcd5KCDx0A7/lVr9jXyf7F8Wm3lR4/7QQJgYyoTg47A0AeM6F4hHhjx3q+nsAJLK9uYbcN/CfMYDHpjNfUPhabR77w8Na1RVfSLW2WxsY5FyzLwGdR13O2AMc4A9a+WLLQbTx98ZPFWn3N2lpPPe3c1syDdvkEh4Hrxk16d4O12/wDBfiYad47Znl01S9kMbYnXpvRehbtz07UAes6VbaxpOvvdXaSX2nxIJ5IQ5kltCQRHHyedqFicZ5OeOtbni34gaZpHhSfVNPmjvrlj5NtbxnLvMfuqV6+59vqKXRtftNM8NpqOpTF77UZPO+zxnfI8j4Cxoo64AUeleK32h32r/ELWPE+lXmnad/YmL25+0c2wlHKwtjjIAJZ/73ToDQB6zBe2nwu+HEureJZ3mvn/AH103WS4uX6Rr75+UduCfWvPtJuNR0u8m8SanbrL8QPE7JBaWhb5bCNuY4MnphRvf2HvXKaD4/Xx/wCMbTW/GaRQCwVToWincsE8563LM2AyrjPt/P1P4S2DeJddn8Z3MjzWMXmW2ll+POYtia5I/wBogovoq+9AHpHhbSF0HQLLTlkaZ4U/eTN1lkJy7n3LEn8a1aKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuK+J/iufQNPtdN0SPz/FGsu1tpcGMgPj5pXzwEQHcfwoAZrepzeJPEsnhjR5XSztQDrN0gI2BhlYI36b2/i9FPUE11+nSxS2ym1VVtV+SIr0KjjgenpXnVppw8O2eleBdHluJdW1BDd6pqIPziPI86ZmPO9z8i+mf9mvSbWCK1tobe3QRwQoI0QdFUDAH5UAS0UUUAFFFFABRRRQAUUU2Rwi5bpkD8zigDO17Q7LXLN7e+SQBsfvIXMbjByMMPQ84PHtXE65rvirwFEsl7p03ijw9EMNeWpAv4F9ZI/uygD+Jdp9R1NeiyzJHncSWxu2qMtj1x171Ug1nTZ3aOK/tmkU4ZPMAZfqOooA5fw38U/B3iCKNrXWoLeVxnybz/R3H/fWAfwJre1W0bWLGaOyvbWW3mQo8U8InhcEdCAQf1rlPFXg7whf3Ml0FNlfy/fksI9/mntvj2sj/iufevDPHaXPhOK4lXw9F9ijwft9u0mkyy890V8E544H4UAbHxhvPGXw70e10/S/ENtDHqLNBDYwuZGVSednmAsg5wPmOKsfA7RZPDkYubVhJHaB5tU1WcDy1IXLQQ/3jx8zdq8f+GlpqXjX4ixX97peq65aWpzJAl1vMYJO1S7tkqO/NfSn7Ruq2nhb4OXVlaQraPeBbS3ghAXaW6gY9AD0oA+XPAnxKHhb4uXviuWGa4trqWcSIhG/Y5yMZ4J4HWsP4geNLjxl491DxDNBxcMFiiY4McagBRkdDgdfU1zK2zfaHiUFmDbMKOp711Ph/wAKXF65ARuAGOeFGPegD0H4dfG270C3is7q7le1jO9IrxPOVW/3vvV7no/xvh1CASQ2+l3mRkpDqCxP/wB8v/jXzvZfD9rxo4EVTJI+1CzBEY+m44A/OrmsfD7SNOgiW6mUXqsyXFuY9hiIHBD5IcHjpQB9FWfxU0qza4kPhDVbdpn3TNbRQy72xjJ2Nk9OtT2nxk8JQhiNM1m1YszMBpbgk9ycDqeK+Nb9dK01m8u4dpVPSKQrx+BrNm1xyCttLe45/wCXh8fzoA+0l+OPgfS4XENnq0EbOzlI9OZdzE5Y445JrD1b9qDwjahhZabq11IBwHRIhn6lj/Kvjedr26JY+cynnkk/qajNhdYUmNuemaAPpDWv2r9TcuujeG7SAEfK9zO0hB+igCvNte+OfxC1qff/AG21iv8AcskWEfiep/E15nJbyRZEqFT2JHBqe2s1usiKRVkz91qALGqXOoapMbjVNRNzM+SXmn3sfryTV3wt4k8QeFbieTw3q0tm9zGYpfIcYdTxgg9+eDjI7VjyWU0bMjIVkUco3BqAxkZ46cEdxQBqaHqF7oGvWGrROyXMMwmSTOckHnP1719ieMvDNv8AGX4eaJ4j0m9i0+/tkMxYBThwPmQnPGCO9fFB3+WCSWSvc/2ZviRD4f1hvDuvtG2h6m3lMJsFEcjAJB4weh+o9KALPgTxveaPeXOnkGfxBITbi7Zt5jBPPlnoAR6cDrXQ6jd2mvXkfgPTZ5/+Ebs7gzazc2oJm1W6Jz9nhA6jOB7YySMZOd+0R4Wht/iHFH4MmaXW7mHzpLGyh2i1gC/eZgcDPUDAqH4JeNtL8A6Rqt0bC1uZ0V5DNKxSdiOqZIOMkDigDtPiF4TPi/W/D3g+SEQaxMFnmSDDR6JYJ0jUjq7cAk8E9OK6/wAItqfw2vLbwrq96U00/LpV9MoNrKo/5ZyH70Un47T2HOK0fgVpd9Do974p8Q2k39veIpBdzStglIcfuowM5ACnOMd/auj13UdK1Tw/cy6qo+y3BKWkcseTLjgEA9Qx/wDHcZoA1ZPEcVlMItXtp7P5d3n7fMgxkDO9emc/xAdK2be4huYhLbSxzRno8bBgfxFeZeD4Na8PQCW0t5b3RpAWl04uGmtMdRDk/MgIwEJyc5Hoe3tYNH1qEXtmqHe2WlgZoZNw6hipDAjHIPSgDaoqpBZmF8/arlxnO13yPp0zVugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM/xDrFl4f0O+1bVJRDZWcTTSufQDoPUnoB3JFeZ+Ec2Onap8VPHh8i+uLZntbd2yLCy6pCoP8Ay0fgn1LAetGvt/wsv4jp4cjTzPCvhyZbnVJOCl1dgZjt/cLncw9RgjpVjxYiePPiPY+FVBk0PQtmo6tggpLN/wAsIGHccFyPQCgDZ+Ful3ctvd+LNegMOua8VmaFuTa24H7mAcdl5b/aJru6KKACiiigAooooAKKKKACkdQ6MpJAIxkdaqzO0N9GzE+TKBH2wrDJH55I+uKtnkHBwaAKDxRahC1veKFnj67GKsvo6kYIz6j3HY1wPiXS761mP9o6Vb+KdNZsB9qpeRLj8Ff6gg10XiTwxqWtyRlfEVxp/ltuje0t0WRB3Ac54IridW+HPiF7oyahrl94lsc5+yvdGycf98YVu/UigChDc/C8pcsNfv8AQ5YxtltJdSmtnT/gDN/Livn3x1qeiXviG8vdHtb7U9JtFYW8t1LJKsrd3ZnPQdgK9S8X6Zo6SyaJp/w9urC4CgXcqpHMwQnPDljyfX0NeWeIdGi8S+N9O8NaFoX9neY6rIpYbo043MQCQMDmgD6M/ZZ8PJp3w+GtSqn2zWZDOxUYCxg4VR7cV4n+1P4yPiDx5/Zds4fTdDXDbTw07f4cCvpbxPrem/DT4W+bCuILG2Fvaxd5H+6oHuTXxLLa3esasbCR4jcF2vr92lCh3JztBPUgHp1oA3Phf4DvdevbeOKHzZ5W3tngIOpZj2GK9fksdK8HO39o3en3MDJuilim4Ug9wD1HoQc1xWr/ABFsPDmmf2P4StLxNQmjQXQjuN6SMowC3AI5J+UGsbwr8LvF3j+5a81eWWG1Y7gXPy9ugoAf4v8AipcakWsNHMlxGrHasaCOLPPzBAMZzznHNcRNaa/q6s17OYIiMkH5R716vrfhjSfBd9DoGg2kmt+KZgNlvEN2wer+lY/iXwFPFC0/jLxJY2VwynFhabpdh54bYCM0Aedf8ItDD8096sgyclR2+ua9Z8DfCqz1S2SW0mE8Tf8ALQKGzwcc15TaoLDVorbTb6CeHhppJm2wJkZwX5weMdwTxXd/BX4iSeG9e1FDAz2lywJWFyY0AyDhcZ54OaAPZv8AhStjDZ7Fl5LDOVAqlP8AB6FAxgKCMLjkH869n8OeJNO8Q6fFcQTIobBxnkH0roPIjZSAOCMcUAfLerfB9midWHnR85G3ofWvKfE/wp1PTGefS1eUR5JjJ+cY9PX6V97raQ4ZWUMM5wap3OgafcNueBc57DrQB+fFg1vqqjT9U3W2oQk4dl2sMehP8qq6hojQz+TKdt0T+6kIwkwx09j7V9mfEn4J6D4wst6oLLU4+Y7uBQG6dGH8Qr5s8YeG9d8CSnS/GFk93pL8R6jCpKH0J/usPf8AWgDzNdMklZxGpWdTiWFhyPp61nXMLW7KeQGGVPT8K764sI5YEvElWWJMeTfrzgf3ZR+ma5uS1k1lpbpgI4h8qKOMn+9zQB75+zB4hsLnT9btbnU4rLxVelf+JjeKJ98KADy8MRwAPXv7V5R8XLGw0n4j3cGnaxYanaSyLcTSWqYhVz/CQCR9cGuPs0vNJuxdeSzRROMsVJTPbPY/SvV/h74N0/4i+FteudPTSLHW4rnz5UaFysEAj/5ZovZjuPQ4PFAHoHhL4g+LvGOmxaBpktrDZNGFlv2jZTj/AJ5qc9COpAPHSvYtIsINOvl3XTeIvEgAUKCBDZqcdhxGgx/vHHAr43try+8J38WnXeoNNpbjMdzp7YMidDgnlT2I6ivqL4O/EbwjHoUenfa7fTpd27E+ULk92Y9W46mgD1+wtfs0Tb28yaQ75Hxjc3sOw9BVG/0OKW9N/YStY6iQFaeIZEgHaROjjr15HYio7/xXodjEks+pQFHYKpiPmbieg+XPPNaWnXTXtss5t57dW+6k67Xx6le30PNAC2BujABfpCJhwTCSVb3API+nP1NWKKKACikZlRSzkKo5JJwBUNpd294jPaTxTorFS0bhgD6ZHegCeiiigAooooAKKQsN4XuRmloAKKKKACiisjXvEujaBC0ur6la2qjtJIAfy60Aa9FeQaz8dNGi+XRLC71HPSQ4ijP0J5Ned+LfjN4svWEemG10mB1OHC73B49aAPpu9vbaxhMt5cRQRjq0jhR+tcNqnxh8E6ZeG3u9YjDDjcg3r+Yr5B8UXXijVg8uoa3eX+Qd0MkhRWA64xwDx1rhsR+YQ5cLk7iQd8Zx/EP6/WgD7Y1P9obwNaRyG3u57tlUsFSMjdgZ4zXLyftT+HRLhNF1F0GeQ65OPSvkq8sZo0DyIxVl3q6r1B7/AEqgByA3Q4AegD7V0f8AaZ8KXt3FFfWOoWETttM0ih1T3O3tXtWk6pY6xZR3emXUV1bSAFZI2yCK/MMu8WzGVYcj0Ir1b4QfF7UPBl3BbTEzaaTgqW+4CewoA+8687+L3jC80W1sPD/hjy5fFuuv9nskLf6hf4p2H91Rn8fXBq4fiZ4eg8IT+ILy7CWkEIlk2jkk9EUZ5YngCuZ+Dvh+91nVLv4leLY9usaqm3T7V1wLCz/hUZ/iYck+h9zQBe1E2fwZ+Eq22lIbvUiRDbhuZL6+lONx9cscn/ZXFdJ8MvCZ8JeGlt7qY3Wr3cjXmpXbY3T3L8ueOw6D2FcT4YZviZ8UZvEzFX8LeGpHs9MU5K3N3/y0nx0woOFP0NexUAFFFFABRRRQAUUUUAFFFFADJ4knheKZQ0bjDD2rEvG1vSwWtI49UtVAwjsUnH/AuQ35Z+tb1V7m1tpTvuI1bbzlugoA5A+PVjDLPYwJMrbWj+3RoynPcPtI/Ks3VfiPdwxOun6VBcXJ4QRXBuOfcRIf5j610VzoXhBHd59J0Z5G+9m1jdzz9CfSq2o6fbwWDJ4fsNWSRhhVspDbqD2yJCFx9AaAPCdbvfGN2uq3pjbT4piPMldBbtIx4HHzOenA4rp/2afBYtptR8RX7R3NyWNrFPtI3YOXJySSc8Z9q5Xxh4b8caleNFfatPFbJJ5UUUW2WR3PB+YKvTOMjOOcV6D40vYfgr8DBZWFy76j5ZggkkOXaZySz/hk/pQB5J+0d8RIdc8XCwsyX0zQiflP3Z7o8D8F5rxzSV1DUbhtP0eN5b+4bdczgZPXtjoAT1qj4WsP+Ei8Rafp95ctBaz3A+0XBGSik5dz6nGa+0PhN8NdEsvJ1K20z7LaQrttUl5llwf9bKe7HGcDgcYoAzfhJ8DNL0G2F3rUQu79ju3vyCQeuD2PvXcfELXW0CztdF8ORo/iHVC0VnH2jGPnlb/ZUHOO5wO9d8OBxXzL8b4NYb41WUdhfS232nSiIcTeSz7XJZEk2nB5BIHXFAFfw3qGleGtc1Pw/azy/wBsfM+o6zOR5k7jBdQxOVUbhz3+gAryjxlqyeJdUay0OKW6h8zbEIgTLekMMhMD5FAJO4jnHFc54gsdYvFvNc1ETtZM5hWeSVEMjZK7Tj5nPyc8c4NfW/7O3gSHQ/DFnreowmTXdRhRpZZFwYogPkjUfwgDHSgDxHQ/ghrt9p8E3imcWdqvKWNsgyhKgEkcAE7RnnNaa/Cjw/O3lWGv3FnfxkCKEptkfOBlSPftX13JbRSLtZBivMfiH8MrfU7drjSS8Fwg3YQnLH3PpQB5X4d1vUPBV7Fp3iRUe0ZwsGoRIUR3zwsg52t+hr6K8La1a6raA28oY9cZ5r5S8Sz3VvYXej69iTyjtdJT1UdME9/8KoeGfiFc+E1e0uJZna1lQLIHPzxZ4J57Dj8KAPtmisLwh4itfEOjWt1BIpeSNXK7gTyODx69a3aACqmo6da6jA8N5bxTxOMMkihgw7gg1booA+Nviz8Kf7I+Jel6R4bnFnp2urIWiLYjRlyzKB2yBx+Nbt/4WsvDDxL9gt7kIgEDSMSISOSMD7w6gg967vxpdi4+I2r6lcx+ZbaJY+RbNtzi4k6498AD/gVcHrt3KdHsUuHWS7kWTcCT8pYkD+WfxoA8t8V2MVxDdpFFHFOQGAjO0bWbIUAdv8K5T4c+NNT8AeK7fWdKILxnZNA5+SaM/eRv6HscGuz8RWslrbmYMAZYlAYtg7kPIFeceIrSWHU52aPasjbgQODn0/GgD7L8R+CPCPxj+H6+I9AsYbXVLiPzY5olCSCQfejfHBPbP0NfLkN/f+HdWls7ia7haJgAsvBVhxg8dM8fUVs/AT4q3Hw48QNDf+bPoF4QtzAD/qm7SqPUdx3H4V9L/EDwLoni1Dq1rFb3WnanAJRLEoI37eJFPqR/L60Ac/8ABn4leEGgto9duUttYYkrPfzFyhx0DNwo9xivW7v4i+DrX/WeJNLc8jbDOJW49kya+EfFngzXPCV6xktbprBWOy4WPemOoJ9OOxr0b4XfEjUbMraw6pqCkqoiS102GQk8ccgHHXqaAPpk/EL7b8vhvw14g1ZjwJPshtYfxkm2/oDTX/4T7VETzrrRPDMUrAKkaNfXA9sttjz9Aa5G00n4q+Jr4yT+IG0DRGA2eZBF9qZcA5KICAc56v8AhXf6H4F0vTbiG8vJr7V9TjTZ9s1K5eZvfCk7Fz/sgUAU7D4eWbS/aPEuqar4iuSVYi/nItwQcjECYjxnnBBrtIYo4IligjSOJRhURQoA9gKeAAMDgDtRQAUUUUAFB4HNFZGuzPK0GmW7lZ7s/Oy9UiH329s/dHuaALenS/ale6AwkhxH7qOh/Hk/lVysvVtY0rw7Yo+pXcNpbouF3t2A6D1rwX4g/tFwxSPp3g2ylu7okr523PtwO1AH0PeXltZQtLdzxwxr1Z2AAryjxl8ePDWiNJBpbNql2uRth4XP+8a8T0jRPGvj+SSTX9UuIrWR8tDGTg5ANet+Cvgzp2lwpIIAJSBmSUb2569aAOMu/H3xC8ZB/sGNGsW5j8vG9h7k1mWPwy1G/m+06peT3lww5lnYlvzOelfQN7FoPhWx8y7khVl53SFVxj/9VeVeKvi1osCSR6bI99KuWEVuN3A5yT6UARad8P4LWMfbJiy/xEHJPsBWJ4otdB01UieaJAisCJGUn3J/CsLwpqHjD4uaxLBY36aLokeTLOhGcDkgepxjrxXeL4A+GWgmD7ba3euXZBaS7uZiwc4HY8Y69BQB4rrni/TIdRaKys1vLOFVMs8bjI9CB3x0PTrWDdaXqGuX1vdW1tDY/aGY2mxS8khGMqcdhkZOMDIr3Lxx8OvA2s6BcX3hKVNP1G1hZ0giODJ8pOAR147V4Ho15Lo11ZfZLOYTRXLGG5DmGV1ZFBQjkAA4Yde/agC9q1lL4eH2LW7OOCZ0LQ7SPKlGSCUJ+42e3Q+1Yg0q2vo2On/K6j54pMZB/pXsPiC1uPGPw0ubrUYFXUbNmO44LOP4XIHAPrjg14BZ3dzp10GiYpIhK/T1/lQBJcQtDiKYFUPQkcoff2qsQ0T/ADjOe3ZhXRy3lvrdjGrhY75XJ6YDZ/z/AIVhXMTwObaRTu9GH3fcUAb/AIT1uNtV0qx12aabQYrlZZLfdw2Om71FfZnxK8WPremaR4R8ITKuq+JAYmkUH/Q7QD97L/3zwPrXwtdafJbK54YJgkjpg9DX0p+yFN/aniS/1TVJxNew2q2VsGPMcY5P54FAH074Z0Ox8N6DZaRpUKw2dpGI0VRjPqT7k5JPqa06KKACiiigAooooAKKKKACiiigApGRW+8oP1FLRQAjbgPkAJ9ziql7FfSxutpcw2xIwHMXmEH1HIH6GrlFAHNaf4N0201eHU5pby9vYF2wvczbliz1KoMKD74zXyR+134uk1n4gjRIJAbLSUCFR3lPLZ+nAr6h+M/j63+Hngm61NirX8o8myhP8cp6H6Dqfp71+ed5Pc6leXF7eSvLdXDtK7tyXYnJP60AfS3gLwbo9r4j8JaXDbW8kqaPFe3d0o+eaWYl+fUBSqj2FfV0MaxRKkYwqjAFfDfwi8eW+na/oU9yrG8hjFlcK3R1TAjYH1C/KR/sivuGzuYry1iuLdw8UihlI9KAJq8T/aVs4b3w9E93aXPm2jGa1vLVHLxP6gqD2617ZVTVbJL+xlt5BuV1IIz1yMYoA+Fvhxe6RP4r0+PxLIgu59ReaV5ICinEO2LfngfOzcY685r7m0lfKg8kbdkQCptGAV7H8q8B8T/Ch/Eesa1e3sEgeZUzIT82V4BB9gBW58NPiFNoNzH4R8fs1vqMQENlqLA+XeR9lJ7OPfrQB7hUc80dvC0szhI1GSx7VnXOuW0YfyUmuGTqsUZOPrXz/wDG74lX1/NN4b01n0+OKL7Rqd2y5+ywdPXlz0A65IoA534+69Y+LtWuYNCit4LewU/btUmkCwpwSE46yHHCjJNeJosmo2cI0XTIzNCWMmo3MmZJs8ABWO1QAcYAJ7k1678O/hwfHsttLeRyaf4VtcvZaYGIlkHeaYj+JsZyeew4ArvPFD6J4eln8P8Ag/TYJtQtUH2iVVHkWwI6SOf4sHIUZPrigDxHwHrd54VuoYL59Q00uwC5B8rPrkdK+0fBN1qVxpkEl+6zK6KyyLz29a+HviEwuIn+a5uJgMFjlV9OFH17+lfcPwyhnt/h/oEV3/r1s4w/1xQB09V9RvIdPsLi8unCQQRtI7HsAM1YJwK4X4qfbbjw2Y7JTIhmTzIh1kHZfpnGfagDyHUdQa+uWgcMs9zM2oXa9Shb/Vx8dcDBNcRfWesaxrkjWsJEcTZ/2QOwr2HwT4FkhsJ59WjkN7ctvfd1X2rafR7bSoUt7SDYoyCepJ96APFtd8KSa1Ywx58mZP8AWHcSM9CfbrXNa/4Gf+zmgmVpJ4s7GReMgDHf9K+gW00zYMQCBjxkdSea4TxHbvb6hNAXjzuH3Sc47j9c0AfOXiLRDb2iTtE8TBBuG3vXe/AX4v3Hgu+i0TX3afw1O+1w+SbUk/eX2z1FJ4508y/aE342AjBOB09K8fuIihxjHfj0oA/RT+yrW8lhubQJf6ddoHR0IaORD3474rzD4k/AS1S6bWfBKtbuTuntFcrjvujI6H2rx34BfGi78B3kek6xI8/hyZ+Qcs1sT1Zfb1Ffb2kapY6zp0N/pV3Dd2cy7o5oWDKwoA8U+GV/4ifWZ9I1TxPqNpIiKsMVzDFKrNgZAZhn8M17La2upRoq3GpRzEdWFsFJ/wDHsfpRqeh6fqUsct3bK00bBlkBKsCPcda0qAEUEKASWPqaWiigAooooAqatqNppGm3OoajOkFpboZJZHOAoFeEeM/jdp/hm2urq2AuvEN8MQ25ORbRAnbvA6cc47k1yP7VPxQhvblfCmh3atFaSCS9ZRlXkHRM9CFPJHc49K8P8PaRc61fCWVmlaRiW3H5nbPU4oA3mv8AxN8RdfNxqF7cMJyTkZ2qO4UdAMV7V8M/hQkbxv5ZVMg7yMknr1/PpVj4S+CQb+IOqqFBJYAZAx/9c17ffX1j4e0wOxUJEoC5PpQBPoWi2Wg2OIwqkAF3PHNeY/Fn412HhZDZaYjXmpSNsSKL5iT07fhXBfEX45wm+Ww02eG4BZvOY7tqL1CggdT64NcL8J9Z0SL4kSeIvGFqXgbKaaR88CS54y/TcB0z3OfegD0vwt8H9e8fsdb+KOoXtpFMd0Ok2zbGVT3cnhfoOfp0rodb/Z18IpZM+g/bNMvYxuiuBI0mGHcjPP8AKu88P+L7PUJs3EiK7HIwxI/D0+lbuoa3HawmRWG3APTNAHxrfQaj4M1uYaTst9YtUb7TDbNm31OAf8tol6KwH3l/+vXRr8RoNQFjtQOjqSxU7ccdx25613nxN0u38ZzB7OJrHURmaznjwJDNjg4H8JHB9a+ZtVtwl/a3EcbWy3Mjxz2wG0W9wD86DJPy4IIz647UAemz6uEZ57IKGxnLc5baB292rk/GthNeeTfQupS5byXlVRxKoLRn2zyv09ataTo+qXEK+VC0qcENknA7duvTvW942tV0f4ayfb1EDCaNoDxmSYMDtX6AEk9hj1FAFr4S6rJrPh69N0dyi3lSYA4HC8Y/HtXk/jXSo4fG2qWFsuQHQZH8LbQWH1zmrPhnxPq2g6jqsPhiIP8AaJWCZXfsByAQPXB4rrvBvw/1UQG91ZTFLK/mncNzHPXJ/wA9aAPK9S02ex8suDg5AJ4wa1NDtYxbG/vGkMj52bevpznsea774keHUsdPWZwfKyc+3HT8K519JkhsdMTzo+bSORlHbcSefzoAwLqRVkuIY+IpPmGeO2cemK7P9n7xMvhnx9F5koWCYY5PB74+v+FcDdBvN2qwZkP8K8HHeoB5kIjuLclZYSHQ+oz/AENAH6c2F0l7aRXERyjjIqxXif7NHj5PE/hhLK8nDahBw64xjn+oxXtZIBAJAJ6e9AC0UUUAFFFFABRRRQAUUUUAFFFFABQSAMngUV558fvFMvhH4Waxf2rFbuVRawMD915OM/gMn8KAPkv9pjxs3i74iz28MhOn6Xm2hGeC2fmb8+PwrzzR4ormGW3f5ZxyjHtis2NTcu5dyZmJbJP3j71LaO8E6OoxLEeh7+1AF6W2mtHFzEpWSF/3m3oD1BFfWv7O/wAQ/wC07GPTppg0gVQEz0NfOVtCNQ0pLmyUPKqkOmPvL3X656VS8JavceEPEVrf2zuLR3GT6DPFAH6PCisTwdr9t4j8P2uoWsiuHQb8HOGHWtugBoRRu+UfMcn3rjfHXgHS/FVjJFeQhyeQAcEN2IPY+9dpQeRg0AfIHxF1nxZ8PrFrSHWotQsFzGiXbt50PP3MqQHHHf0rz3wtbHWtZNneqJEtC2oajK5/4+Lg/cRieirnGPUNX1D8TfgzoHiOK6vrmXUDPhmjRZvkRiDggY9cV4N8P764+F2ueJLXVNDk1nSruMRzEJvcMhLxuRjlTnn86APUfHHiibw/4S0/wvoIWDUdVi8y4uEdWaKDADEjBwWztXkEYzXCxxrZ2MWk6cqwwyEGVYzncx5wSeT6k+tQaM2k3pvdcvtSsI3u2+0SkTKVUdo0UngDoBjtVnw5pev+K9T8vwtbSQ2p+9qVzHsVc/eMaHlmx07UAT6D4TPirxbZ6LZIHsbKUXOpT7cgnPywg+vc19a20SwQJEgAVQAAK5n4f+D7HwjosVnZxnfkvJK/LyORyzHuSa6qgCG53su1FzyKSCALGm8AsOenep6KAGuiuMMMiqN5pcNywONh9RVXxH4m0vw/avNqN1FFt7MwH868xb4v3es5tvB+kT6vfbfm8hT5URyfvP27UAemXOjWscLl5tilcEvjgV494osfD9jLMsutb5iSwVSMjmqupeGvHmvxSz+I/En9noSwFnp4Hy49WPJ/SuVvvhjp7vI17quq3YztJkkWPIx7fX1oA53xRcaeEnFteRSkg/Mxxu714prSxpdShCMbiM5z3r2XWvAnhmGKZF+1w/KT57OZCO3PY815F4i0ZdJnMa3CzLk4KnoPcdqAMrULU2V7NbmSOXyzjfG2VYdiDXffB34rav8ADbU2Nt/pWkzkfaLJ2+U/7S+jfzrF0XR5fGetTw6XZQWs0rIscEWQm7aQFBJ6sR9MnsKztb8N6npKB9QtJ7csiyBXjIO0kjP4FSPqKAP0Y8DeLtJ8a6BDq+hziW3k4ZTw0bd1YdiK6Cvzy+B/xHvPh74simEhbSbphHeQk/LtJ++B6j+VfoJpt7BqNhBeWrh4JkDow7gigCzRRRQAV5b8ffiTH4C8JS/ZGVtYu8w2y/3SRyx+g/pXe+KdZg8P6Be6ndMFit4mkJ+gzX57fELxTe+PvFsl9cbzGW2xR7iQinoB7mgDmYEk1LVQrOXlmcs7tyWPJJr6n+GXhFY4kHl7UK7iWHP+elfNHhxIbTxJa/aPkCuPvZ4NfdXgOGOSwilR8Iyhsk5yMetAHR+G9NSxYbAAqKcnHBrwP41+I9S8YeOLXwT4OcyXbttuZEGViBODk9sd66P4vfFhdJuP7E8OI893LuiQRfeaQjHH0ryL4KeO4fBmpajqXia0vFub9wzXjREh49pG3djjkg5FAH0f8Ofg14X8G6YqfYYdQ1Jk2zXc67mY98Z6CsT4h/Buw1Rbi98Kww2GplQZLGVc2V4AMbXXscdGGCM11fhL4h6Tq9oZ4J1khJADowbj3x0rc1HxXp0FuJIJ1lJJyFHPHtQB8f8AhvVpNB1R9G1pLmyjSZoI1kJ32sgbmJm4yMcqw4IP1r1NzrtrZNsnkuLfspJLHJGOcdPpVT4/6VYeINFPiq1iKeTsh1PaD/qy2FbjqyEg81wPhH4r6j4O0qXSb+2a+e2zCJEG4HB4+YHBHP8AKgD2bwLpdzDcy3+oxCPaNqEgglj0G5uST7V87/Gi60lPHni+z0xjJGJ4nikjcbVnUASDpzyzDjpjvWnrPjbxr8Q7uOz02OS0tmO1YrbIYepJHSu08D/s+TObOfVxufLSEZ4HTFAHj2ka54vdXt9DEqhz1jXcw+h967jwV8Gdf8Q3cN14leZ7fqEkc9zz16D6V9UeF/h3ouhRKsVrEzDkEr0NdfFbwxJtjjUD6UAeM+EfhNo/hqBjbWvzHlgxLcg1u6lpsRtTHFGAR2A6HtXo81uroQvDY4Nc5qVgxLbcZJ7DoaAPnn4vWIv9MttNhUGa7nwCf+WeMFj+GP1ry7Us/vRCDhUWBGxzhRjI9a+pfEvg2XVgJI5BbvtKM+ASFPXHoTgc1hR+B9KsbdVeBZmRSOeeaAPk660a9W+ykTFJWxnBwDxycdBVkaLcbWhIWORSXjwMgj0HrX0fc+HtPuLt0eziUYYh2JGCPXn0Irm7TR7Frny5dPn3IT5ZBOAcEZH14oA8r8AS6r4S8XaXrFr5sUbzLFKinqSeAcdia+0PFniJbbwZZ+KI0bZYTRXE8fQiNjskz6YVyfwrw+30SIQSECOWIY+VlyVPXJHqDXrfhW5g1Pw3PpN6u63vI2t5VZeoZSD9KAPTYpEljSSJg8bgMrKcgg9CKdXCfBq7nPhE6RfszX2iXD6bIW6sqH9234xlK7ugAooooAKKKKACiiigAooooAK8D/bMaQfDGyVVJQ6jGXPphWxXvlef/HjwsfF3wy1awhQPdRJ9ogH+2nP8s0AfnjGjkF4gSR1wK07O1OoLuiz9oUdc43e31rPt5pLOc8YZThgR6dq1rdXjkN5Y8EZLRYxkdSR+dAGp4XvJNHnNy0Zltgdl3Ac5Xn72P511GtaDDqFn/oKSSpLh4mRRtdTznPtUnhyFNcsEu7S4jivYVIlXP+t/3h16d60fDcs+k3q6NJHKbW4lX7P13W8hP+r9NjE8ehHvQBJ8DfiHe+B/EH9karI/2ORwuG/hzxnn8K+19NvYtQs4riBgyOobivjf4keF4b2zt77TRFFcAbo8H7svdT7N/Otz4K/Fuewlj0zVpCjRHynEvVcev8s0AfWtFZuj6xbapapNA6/NjjNaVACOodCrDIPBrmj4Usl1VrtYEJYYJPWumooA5X/hXnhMSGSPw/pscpOS626hs+ucdfeuis7K3soxHbRJGvsKsUUAFFFZ+u6va6LYSXV7IqIo4yetAF2aaOCMvM6og7scVweteKdV1q5l0rwRaebOp2zajP8ALb259Cf4m9hn8KzfDkWq/ECc6lrCT2Who2baAHa1xg/fPovoO/U16VaWsFjapb2kSQwRjCoowBQB5hD8LdFtVOoeL7u51/UPvn7Ux8hTxkLEDjH1zV5taR0mg8P2SjaNgESBFwMYAA7CtHxhq+n2tlNPqV3DFbR53u74XGOnNfOnjz4/xwJNZ+EYELD5Uu2QAD6CgD1u/tdXvIhJqdzBZIGJbzJduPwFcXqd5pFq7RTa/bu4IDJHySPTnv7182a74x17XZnl1C/nl3fw7iABWC8spbcXfnvQB9MXGq6RPGYonLxlDk+aAxP8q8X+IsKpeM8Ll4WI2ZA6cjn3FclFcXEe4rPIMDpuNSXmoTXECRSknbySe5oA2PCmrSaVp+ovAwEkuxBz9a7DQvEEl54N8X2mqGG4tU00C3LR/OJjPEVIPXgBj+Z715jaHDYJwrA55x0roLUmDRtQH3hMgXGTzyOf8+9AGVerZzaYlxAqQ3KzFGjUnDoRlWAJ7YIP4e9fdf7M1zfXfwm0uXUXZm5WPd12DgV8ReG/D9z4l8TafouloZLm6dYuAcIO5PoBX6PeF9Ft/D3h+w0qzULDawrEMd8Dk0AalFFQX032eyuJsgeXGzZPTgUAfNP7W3xAa1tR4Z06cB5hm52nkLnpj3r5w0OI2timobFlQSETLgblB6GmfEXWX1/xtq1/I+4STsqnH8IOBVPSbyayXYNojlHOVzvGcEUAdZ4r0cXmiW/iDT8SeSQJghHCj+IfpXo/hz4r/wBmfDC5jMqtdRbYgvQsCvGB19a8z0O4bSLp2YH+w7o+WzMOIywPBHocEVk+ItHGh+I30ueVmsGkWVWjySYyecD1xmgD0H4I+Dbf4heNf7R8X3EUlgC0rW7TBWlPYYzkL9OtfS+q/B7w1c6fdReGw+iTSxmMvaSMVIIHDRuShHA7ZrhfBXgXwZ4x060fStNs2sfKJVoxscuBw24cg/Xmuut7PxF4DWI29xe6pocWQ9pM5kuIF65jb/loBj7hOT0BoA8D13wnr3w+1VomP9i3kzlY7iNiLC8ABPDZ/dOeBtORk9q2fBGq6j4xb7BavczajbsftFtKmChHGSARkepr134navpXinwM4uI0v7C6hZrWaMYXeBjcGP3WU8EHkcgivlXXLbVNFngBupLTU7eM/wBn3cBKm6gztKbl67ecE+hHpQB6t8WNek8P+CJ/C5uTca5rbr5ycYhgU9OO5NQfCz4Q3mrWfn3CMlvIQSp4wPSl+BfwuvfEurrrXiRrpwhDu06N8/ooJ619cWdrDZ20cFtGEiQYUCgDmvCngfStAtEjhtosjHReMjv7murAAAAGBRRQAUUUUAFRvBGxyyAmpKKAKN3bNIpVI0C/59q5/UtKgnSSJpcscjajAdRXTX0tvDbmS8dUiXkljgV5p4y+LnhbwzDMEnheZB91QPm9v/1UAEnh2GEN5EPJP3gSSOKzb7QwEcSSrAMbg68MvHrXAP488e+Ob6NPDeljR7GRT/p18GSML6gYyefQGox8K9SuNKI1/wAeX4uCXLJbQhof+AlmDH8hQBau0tbWVWXVwZMfMrMM5z0OPxrRj8TabpFtHcRXMchSTbJErjdjntmvKX+FeilGU+K7t7kHj92u3b7/ADZ/nXP+IPhnfWVv9p03U1uo84AJwx4zgYoA+gvhv45gPxnuoAyiy8S2iPFgj5biEHr/ALyH9BX0DX5raRrOtaLr2nSb5FurC4WeIlsMCp5wfpkV+i/hrVE1vw/p+qRLtS7gSZR7MM0AaVFFFABRRWfr99caZo91eWenz6jPCu5LSAgPLz0XPGaANCivMk+JeuMFb/hW3ioJnDfLEGH0BYZ4/wAKbN8WJ4Cpn8A+NEV/uH7ArZ/ANxQB6fRXmP8Awt+2Q7bjwf40ifBbb/Zefl9fvU+1+L2n3UAkh8MeMCMkEHSiCAO/3qAPS6aSpYocE4zg+leY6n8UNIntWj1Lwj4ua2Jwwk0dyB79a4O7+IMVlqCXPhnQvHEUSy7niNnI8JX02PyAfYj6UAeYftKfCi48M6/da/o0G7Rrp/MdEH+pY9ePTNeM6fJKik2wyufmQDJ/CvsC8+L9l4lsbnTtV8F+JWSSPbIosSwAzgZHXmvlnxroVzo2rz3un6Rq+n6Q8mYGvrZo9vtkj/69AG74cLSqt9o06W14BskQY56/K6n1/wA+legaTNaeIIorK/TydSTjy84JHcox+8MfjmvErPVIPvPDNHc8hZbfGfxBrpYPFk/lKNR0qWdY2DJOiFGHHX2OecigD6C02e2s8WGqK88dyGSRZG3iUZPzhvXn6givFvih4Zl0bWGvtHaWQhifMAP71RyCf9oDGfzrSs/iNdahpz2d5oN9f24GVkUYYepPGD9asw+J9bv7MQ/8I1dXkRJWCWVghJHT6mgBfhl8YrzR5Egu5f3BIyCCSv0r37TPjRpMgUzSo6YzuBx718wzfCTxXrtzcaha6dZaeGfP2Y3IBXsT/WtuP4FanZiJtR1iwkVgCVjucAA9iMFv0oA+hdU/aA8FWClVuZ7q6PC29vGZHJ9OK4LV/jR4x18ldC0uDw/YtwLm9IeU49E6Vjad4F0nw/CDYTR3Fx1xFEY9o95G56jtWXbaMdRvDbtM0ueVgtcvnn1/xNAHtHwlvlvLpBd6tqusX4JZpnkKxr7bFO0Ac9jXrxYBgD1IzXAfCzQk0Sy8s6XLYPj5fMdWZx1yQOlegUAFeXeJ4F8Z+ObfRAC+nWaie9IJwQG+RD/vEHI9BXa+NtetvDPhi+1W9bbFAnAHJYngAe5NZ/w6sJrPQPt2oqF1TUm+2XIPVCw+VP8AgK4H50AdQix28SogCRqMADtXl/xf+KNj4S0icRTIbsr8iZ5fPGB+v5Vp/Ezxpa+HtGmmnn8lQjYYDJZtpwo+p4yfevhTx74qvPFmvTX104Ck4jjXhUXGAAPoKAJ/G3jrW/FkrpqFwy2ocstuhOxeeB71ywjOCT/OnKoQfNwT2IqN5CenA9BQBMXCPnIxxx68VGJuVJHQ54qIDJo70AWmdGi2gYPPf8qryElj/KkDHGPfNJ1NAEkEnlurAcr6cGtnT11DXLqDTNJt5ri6mcKkaDJJ/p61oeA/h/r3jTUobbSrOTynYB7hlIRB3Oe/0FfbPwg+EWj/AA7tvNjAutVdcSXLjkew9KAMr4C/Bu0+H1qdT1FhdeIbmMB5COIAeSi/1PtXsVFFABWP4xZl8K6syEhhbSYI6/dNbFU9ZtDf6Vd2oOGmiZAfcigD8u5mLTu3O4sT+taWmeXPH5VwzbQexOQeMGrPjrw/feGPFN/pmpQtFPFITgjGQeQR7VW0a0W9by1mEUwOQe/v9RQBtaVM1hdXFhqO57G4Gx/l4YEjBB9QQOexrY1qF7+zfSp2MmpWC+ZY3bZUzw8HB9GA/lWPYNFM507U4ysiHaSueg7g1q6pZTWzf2dfswnjPm2V2MbZF7c+vqKAPZ/gFcy6jZfbPDkkVr4htQwltpDi3uzjlHAPDHHDjpnuK+hfCXiWx8V6fJ+6a21C3byr3TpyBNayd1YencMOGHIr4m+GevTeFvE8OpRbkML7L+LPGwn74Ht+WK+sG0XRfGstrqYkn07xBEmLfVLGQRzbe2SOHXn7rAigCv448L6b4as9Q1iO3WTRJpVuNQs3GUik+79pQdjyN47rz1FebXfh638efGDR9Ntkjk0/RrEz3EsYxGGlcsqr7AfrmvU/Enh7x5q2h3GhS65oUtndIYpr42TrPsPUeWGKZPrx9K3vh14HsPBOlywWjvcXdwVa4upQN8hAAA9lAGABQB0enWUGn2cVraoEhjG1VFWaKKACiiigAooooAQkKCSQAO5rmvEXi6w0m3kdpB8gyXONoH41yPxZ8fR6DaGNHQlnCJEDl5X7ADvXmuj+CNd8eXsT6+ZIbF2Dm0V8IFz/ABjqx/HFAFbxF418RfErUjp3g9CliHKS6jJ/qwB12j+IjP0rX8N/C7S9BeOe5hl1fWCdzXDp5jA5HIzwPwGa9q8O+DtI8O6cLeziSONFxnAUKPp2rzb4n/GvQPBHmWejeVeaiOT5eGAPHegDqLfTNcuIWIheME8tN98g9Ryazr3wnK4ka/u4vmBGxpsYyPavlzxl8ePGfiJmWLUPsFuTkR2w2n8/pXnd14g1e7d2n1K9kZ+DunY/1oA+wIPCltFIEt7rTpGwMFWyVOOc1NeaXNZ6M7GCG4j3jmLB28Hn1r4thvruFt0N1PGeuVkIrptE+IfijSLqOeDVZ5Qh+5M29T7HNAH1Ja/C7S/G9uy3A8hM+YZgv71D2x6HP4V6Z8KEvdN8Py+HdXZH1DRZTbGRAAs0RG+KQAdAVbGOxUjtXBfs3/Eyx8XWtzp9yq22sJhjFuJDqB1X/D6164to8Pip7uNT5V1ZiOQgcBo3JXPuRI3/AHzQBrUUUUAFV9RnltbKWa3tZbyVBlYImVWf2BYgfmRViigDmIvFv7iSW80DX7QIQMNaeaWPGcCMscDPX2qnJ8TvCVuSt9qv2CQHBS9glgb2OHUcV2dNljSVCkqK6HgqwyDQBz1r468J3ZIt/EujOQQuBex5yeg61uWt5a3a7rS5hnX1ikDD9K57U/h74O1NGW+8L6NLuGCfscYb8wM1gT/BPwBJC0cOgi13EHda3U0RyOh+V6APR6wPFdxe2sAlgv7CytQPne4iaR92f4VBGeO1cY/wZ0+FlfSvFXjHTnUgr5WrOyj8GBqs/wAM/GFrcm50z4mam02zYPt9lFPx9eCPwoAkspvE/wBtuL7T7eYW6rk3WqEW6MOvyQqu4jH94iurSzsfHvgd7XXIra7gu0ZJNiMq57MobkEcGvKvEkPxTtr1dMj13R9fDp5ph+wtESqngMVPGTgda5qP4k/Ejwfqgn1fw1ZPaO5gltoZtod8cMpOduB1PQ4oA8I+J/gjUfhz4vn0y7Uy2xJe1nZflnjz1+o7/wD6qzNG16a3yqzEKSpMch+U884Pbj1r6Q+Mj+Kvif4QtYT8OdRt54nE9vdxXUM67SOcYIOCMV8rXNjcWl3Na3kEsNxCxSSN1wyN0wRQB6Np95bvd7rOZrC4JLAKfkcj1HQjmu00zVJbSMSXIEYYBSYwHikye4zlOnXnmvCIZLixkzHuIB+66HB/Cur8PeK0ikVJZmtlwQVfLxnPv1FAH0Rp2tw3FhCLW+hgkZziUAFx04wTg57Eim6gqlhLea/dFCATiFAD26ivJ7LxHJcTLHbvaPgnZtcY+mcfjz61saT4j1C0lktxCkc/eOdyPrzj8cUAd7azeD2s5luJtRvrg/d2ZxyPTBqja297Zaikuh2tzY2LsCGchQffB5P5Csu7vryfy2eC1hOM71nJUn1BArq/hxYapqt2kep3Np9gBJ3PcAMwxjAHU8kflQB7f4Nubm50uKS9ZGlKDDD+IV0Fc94Usp9NsUtpypSJcKwPUVvs2ELDnjI96APIvj3Ol3qHgzRZXItrvVU89B/FgZUH2zivS5b1IBIfcKACOleF/E2/W7+M3gi0kL+XFe7jjpu2E8/TAr07xJcfZ9LnYP8APsPVsevegD5o/ac8Ufbr+20m2lXyYhvlSMgjf8w5bucY9uaxf2ffh1pvjW/lk1ItIInI8vJChQucnuTzwK4bxzM9z4nujIW3GTA+melafgrxlrHgaUXmjSIJPR8kEZ9O+eRQBrftC+A7LwL4hsrawuRMlzG0hUfwEHp7cEfnXk+OK6Xxl4r1Pxjq7X2rFDKSSFjXCrn09Kwgo3YzjBz1oAhC4Iz1oK4XNSnnknkcjHNdF4F8F6z441ePT9EtTIxOHkx8kY9WPpQBg2Gn3WpXK2+nwSTynoqDJr6T+Dn7OM12kWqeOVMMBAaOxU/OwP8AfP8AD9Bz9K9o+Efwh0XwBYI5jS81ZgDJcOuQp9E/x/lXpU0scEbSTOscajJZjgAUAVNG0ix0Wxjs9Lto7a3jGFRFwMVerNs9Qk1GSKWxjH2HktNKCC4xxsH9T+Ga0qACqF9rOl2Emy+1KytnxnbNOqH8iav1XvLG0vU23lrBcL6Sxhx+tAFCLxNoMzssWt6W7KcMFu4yR9eatwapp9wu6C+tJV6ZSZT/ACNZs3gzwvOAJvDeiyY/vWMR/wDZaxLn4SeALmRnl8JaQGIwdkAT9FxQB5f+1r4LttZ0S212zWP+0LcFGZcZdBzya+OEZkcYOxlPDdCK/Qq5+CvgOeExf2K0SntHdzAD8N+P0r5o+PvwUHgwJqnh/wA2bTWJEkbZZk9CD3H9aAPJf7ROp+XHeukVwvCXAXBP1Oa7b7RPKBoPieCNd4AguM4CvjhlPTP6GvLlxnkH8K6SIPNbwx6jf3cmlcBXjbIi9NymgDt9FjuU8QW9jeOhvFDpFcMMR30WCDG/pxkeors/B/j1/Cl5/Y15M62sTbrWd+qJnHlv6MCMZ6fpXndpol3PdRQ3ur3KafIc212QJEU9gW7ex6c9s1uzeCda1i/ltdQ1eGG5RgElltMM68dWB5wOo5oA+sfCnjJNStVlkKlDjD53fUV2kFxHKgKtjPTPFfIPh7w18UfB1ybLT9Nt9X04/vI2t51CSBhwVJOfwxXoGha58TIrYRT+DizhtgZ72JM5PfcaAPoPcPUfnS14/Bf/ABGuJG82z8OaUpwC9xqJlIByM4QVfuHv7K1eTX/iBY2RbgJZQoDn2LliT+FAHqNFeWeBYNav9e+2WmtXdzokJx5l0p3z8cj+76/dA+tep0AFeY/GD4kw+EtPeztI2n1Sf93DEoySx4r0TU7mO0spZZThQpPT2rwfwHocfxC+I2peI9RT7Rpdk/kwq/QkdAB+ZP4UAaHwt8Aajqd4nijxhJDcahLH+4TbuW2B/uA8ZOevWvVtSvdK8H6DcX9/KlvZwgvJI3Vj/jWs7wWVoXdkigiXJJ4CgV8MftEfFS58a65JptlIY9Fs3Koin/WMP4m9aAJ/i38fNd8VXlxZ6FK2naLyqqn35B6k14rIzyyNJIxZ2OWYnJJpoBJFOYhCNpOetADcYqQvjG3A4xkCoqSgB6gHjinpHuwOhJ/Soat6ejPOgx8ufvelAHoXw1kufDfi/wAO6zaMY1N4kcjEcMrEDB9u1foKCS+MfLjr6mvgbRbSW+0cRxn97GUMEYHV94wPfmvva0jaK1hjkILoiqxHcgUAS0UUUAFFFFABRRRQAUUUUAFRyhyBsxjvmpKKAOe0nTpPt97eyhA0jLEMLzsTt+ZJrAv9HbXPEUtzLGrWNjugiVgPnkYfMefQfL+dd3chzbusOFkYYU+hPf8ArVSCCCzjjs1AAA3D5fvHuc+ueaAPMPDviZfA+u2/hzVnC6Tds72c7Hi3wcmNj2XkYP4V5f8AtGeDLa9RPG/h+JxFJ8l2AhXzE5HmAH+fpXovjnwynjTUdRiGVtbZfs7MMDlTuOPctt/75qP4b6xb+KLDWfD3iC5i/taG4+y+SeBIojxuA9Dg/iKAPmXTLSHVLOKSBfNcDaQOx9Kr3fhRWifbZyIFznbjIz09+1avi7Rrz4YfECaznEg0+X97bb8hSM8D8Oma7XSfFOlX7KshKkgcbc5+tAHht9oF9Zjz4Edoh0YcEetaGn+IvOEUGpySxvEAiTqc8ejDoQK9vnk0eV2jJTawJAIP05NeSeOdA062uFksJxscFipYfL7D1oA3NP1dYoV+0ENGRgTR8qR/tL2+teo/CzUpbbWHjne3kso4jMheVUOOvy5+8R/d6ntXzNaXlxp0+baXdEeqnkHPXiu98HeJLC0uYY79R9hmOXiZCRGemQewOenqBQB94218k1tG4HysOCOnSm3d+kEabiAiEEsT29K8Y0f4q+G9O02C1OqpJ5QABPOB6Z9qyPFfxl0lrR4rO6SUsMZBz9P0oAoebDrn7SNkikTxWlvNcx7em/GAT+f6V6v4puFksLiLC70UnbkLnjpXyp8PfGMFj8W4tXlkMkEqmIs2QOTivojxNqlqX+2QsXDgfKVPNAHyTriNN4ivBIFZmmbnp3qPWYmjtOWOQMbeKueKIGg8S3rSquZJWZPlJ71nXNynkssj+ZIxH3TtC+/1oAxoBgJxluvSpDGEXLLzjJ6etXtB0rVddkuIdFsZr57eIzTCMZEcYIy7HsvPU13nwl+El54+8Q83KnRrRx9su4x8jNn/AFcTfxHHVug/LIBR+EXwq1b4j6riASWmiQti4vWXj/dX1b+XevtXw3oPh34daAtnpNukMSgBmAzJK3qT1JNZurXemeBtAg0nRI4bO3gQD5R8sa5xk/ietcXda3dajqBWJJXneF1s1Ucbs/6w8cD0PpQB6Jc+L4rJ7g6krwzRjMUA5MgPTA7nt9azND0fX/EV+1/4mutlgr7oNPEY249XPc+3IpfCXhx9Rlj1HX1L6jGAM84j452fX1r0NVCKFUYAGAKAAAKAFAAHAApaKKACq979r8sfYvI355E2cEfUVYooA5u81TxHZlj/AMI7FfRgnH2O+UPj/dkVB+tY83xEksXYaz4Q8UWUajLTJaLcxqPcxMx/Su8ooA89g+MvgOQhZ9eSykP8F7BLbkfXeoq5r+r+G/Fnh26ttP1jSb4tHkJHcxuSD7A5Fdde2VrfReVfWsFzH/cmjDj8jXHap8JfAepSNJceF9NSVjkvbx+S2fqmKAPjH4k/D6bSY31fTIybLfiSPB3Rk85+nP6Vwtpcy2cjsp8v1wPlbHbFfbGsfs7eGLqB00vVNe01m7R3pdCPQq2ePxr57+M/wXvfh8iX9pdS6hpzN80jx8p9cfhQBX8A6vbLqESW6JELhWE1nOwNvJkHJQnO0n0PHtXtFrpEF9peydrlFiG6F5OZLVh0we6gHp6dK+TdLFz9tVrBTIy84Qcceua9T8C/FDVfB14sHiCwuJtNcbGjkJ+QeqE5x9OR7UAe0XNlqLXKLNqk63EEYjlicDLYx0YDO3HTOT16VCLvSYgbfxDYy3qc7ZoXZHA9MqcEfhXQaJqvhvxlE91oF0lxPGAhXeEniGB93sw6dMfSro03RbiRIdUxb3AJUPMvBJ9SMbfY5xzigDktOsPhs3M6azFsIHziUA85xkcV0dq/wySOU2qx+YoBLSQ7mGOQcuOOntWkfA4s5t/2u8tQdyh4h5kajrznkA+9Xv8AhA4dThUnUYLiJ+WZY1yfxH8qAOx8Lz2tzo8M2nsjWj5MZTGMfhWtWPoVlDolnb6ZZWriKMcuq4XPrWldv5dtI2cYHWgDzP43+LYNF8LajFGSbp4yke3+8eP5muh+Enh8eG/Amm2bKRO6edKTjO5uSPwzXiHxFnXXPiN4W0AP5i3eoKsvchEO48+9fTF5Ktvasw42jgAUAeGftTePDonhttGsZMXVyP3hB6D0r4pYl3JJySck16r+0drD6n4/uYzI7xxcgMc4ya830NraLV7SS9aRbZZVZyiBmABz0PB+hoAS+0q+sbaKe6tZooJSVWRlO0sOoz6+1UK+gvjb8W/Dfi7wpJoukWs/mrJHMk6p5cbN/F8vUHGM9ifpXz7QAtAFAp8aFyAMfjQAJGzngd66DStMZk3DHHJJPAo0XS5JGHB5OOld14X8M3fiXxDZeHNPVxPdMDNJ0EUY5JP4An8KAPS/2aPBDa1qTa9exN/ZlkwS3Lf8tHBz09Ohr6rrK8L6FZeGtBs9J0yMR21sgUccse7H3J5rVoAKKKKACiiigAooooAKKKKACiiigAqnq8C3GnzKwOQpYEcEEc8e9XKKAOK0cjRfDMlldoPtgV5FYj/XOxLfnk14l4jivPB3iC38TadGZZNI/wCPn5eLlpOZEGPTJr6H8VaWdS05khjUzggox6of7w9xXj7X88upW3h/xHDDDHbF2huipCXco6Ak9G5JI9aALHxX0jT/AIw/CL+2dG8t761Rp4ivLBlHzJn86+Wfh/4F8WeMbPUbjw5btJDYLmRmfaCcE7F9Wx2r2rwh4muPhr8WL/QZ9raJq0gMcZbEcbMeSPrXp37OcFrFa+NxYLGLN/EFx5aqOAuxB+Wc0AfH9n4ut4LS4tdY8OWF9cgbI7gSywPGQechGAb8hyO9YbpqV9Lugs7jaTlVRHYD6E5NfUXwO8OeDotD1PW9UgsW1SO+uY5WumXMZWQ4A3Hj5cV02tfFLw1peq20ek2cGoRlH88WcXmND0CsGHy9cg+lAHyjpXw/8W6oA1toGpyKe4i2D9a67Tfgv4tuMGTw5MR/03utv6AV7sPiH4uj06WNdIEcGC0V1cMNyjtvVM+3NS2njTxA2m6VcRPDILkKszgED5hnI9OaAPI0+AfiTyN50GwJB5Qag+7+WKzb74K+J4+F8IXe045h1BX5/EV7Nq666bqW/wBMuZoLyTckirIwSVSvcZ4PoRzU+h+LPEV1oKidpRcQ5hn4ySwyM/XoaAPnK7+G2tWMpMugeI7YJwXjjWbHpjGKgRtUsisUfiO5t2B2iHUrd4gPY5yK96l8eeJbbwzqWmXkEU01vEV810IcqfuEEdT7+op03xS1ib7FZ6l4QhvRHF5t0wYEkbcAjPQ5GcUAfNV+2oxyJd6nZpeWxILPFOSrD6qTiu88J+IfDWv6nY6N4e+FGm3OsXB2K11qc8ikgZLMDjjjJ5rubzW/AWs6ek+veAbq1eX5vOsoDHtXPdkIzxWh8FvDnhgfF1L/AMCXF7d2cOnzNdfaR/x7M5VUTcRncRvPfpQB5Rrdh4n8XfFO38MyWdhpE8qrZta6TD5ECQZ3HIHLjjJLE9BX2Hax6N8O/C9noWmmKFYIvlHQ4zy7fU559a83lvrfQvjx4gvpLaASW+l26faJCFSHJcks3uAvA5NRRfb/AIk+NEeRJIdDWJ1DAFTegMvPPROMAd6AKj6rqHxL0vUrWy2rYQyMk06DJuSDkAc8DAH1r1Dwv4at0t9Kuol3ZCu7nkn5O/p9KpaH4H/srxPeNpMgsIGihl8hV/dsRkN8oIwTjqK73Sre4tIfJmERTJYFGPGT0wR0/GgC8iKihUAAHYUtFFABRRRQAUUUUAFFFFABRRRQAVR1rSrLWtPlsdSgSe2lUqysKvUUAfD/AMSfhbd/Dbxol3bpJN4fui/kzKpOzI+42On1rrvDOkWOtaesdxFHJDKDy3UfhX1Vf2dtqFpJbXsEc9vICrxyLkEHivHNS+Gd5oOqvceH8S6cxLeVzvj9s9x+tAHiOt/D3WPBuojW/ChlaNG3GBCVZeOdpr2H4aeN9P8AiTov2DWF26rDlDIuEcZGM47HjkYwa6q3hluLVYzCmTt5cNxnIyR+GK8W8ceCNa8M+II/E/hVRbyW4Ej7ASMZ53L3HBzQB6jpviTVvB2prpmsK+o6XIC0TquSUHdCTzhfvRnkdRxxXc/ZNJufs2s6S8sErhZFa14WQdMMp+Ujtk4rzhvF0niHwOL+4sYV1S0CSNBltrHdxJF6+h9MkVt6NfS2d7LdxJCmmyru+yZLGKUlScdhjkkdDQB6payNLAjOGViOQ2Mg/hWd4huDFbpEMYlyCcZPGKjs9ZSe3LY29cEYHGM5xnvWF4k1rF1aHGVUE8ZwcjjPpQB4paQkftMeHo7lgUjjuJ1B4+bY2BX0B4wlaLS1kDbRggnPtXy18QvEz6H8U9D8RxxIPsEnlzrnIMbja2fwJr3+fxrYXvhyFHjaeSSIHAOPx9qAPh74lTvd+NtVkkIJ84qCPQCuaCZP8Kjmuw+J+nS2Pie8m2YiuXLjB4B9K45uMg4B4oAjPBPegU4qeSAcU6KJpD8tADAMmuk8P6W87Bm4yO5xUuh+HJ7qcKITkAMc+hr2Xwl8Prq7lit7C3hnvSPuH7qe7N2FAHK6darYzQ2GmW7ahq9xxBbx/M5P0HQV9RfBv4bjwhZHUdXdbjxDdLmaQfdhB/5Zr/U1c+GPw007wYJb6Tbd65cj99dso+Uf3U9BXoFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRVPU9Qj0+AyNDcztjKxW8TSO30A/riuOvPEnja+lli8P+DEtkBwl3rF+kS/Xy497H8xQB3tcR8SLfwzFpH/ABUNzYWcLMW/0iQJuPXI5znPcVkS+EfiBr0W3xD44i0uI53QaBaeWcf9dpCW6egFWtJ+EHgzS7n7ffWMmrXqjLXesXDXTfX5ztH5UAfPWlaJqPi3Wrybw3Z3GviRWtree8Vkgtot3ys0pxux1AXJ6V9MfCjwUngPwdBpH2k3d0Xa4uZ8YEkrfeIHp0H4VR1j4o+EdElGnWFz/aV+vyR6fpUXnOT0wAvyj86zW8V/ETXIyNA8Ex6Sh4FxrV2FPXr5aZPr1oA5nxX8GjbeL73xJ4Xs9PvpL2QyT6ZqceYCzclo2H3D9QRU9nZeLrS5nluvh1bOJFWIJZ6jCqqgHIwcdSSa6OGx+LYhLyax4TMpORGbWXao/wB4Hmrxb4oQxqdng66YDJUNcxEn0BwaAOas38UWcfkR/D29kgUELv1K3yq+n3vmxVO1sPF8ekxWdv4EcGOQNvm1O3XgNnAAJrqZNc+JsQ/5E7RJz38vVyuf++kqu/iv4mI+D8OLVxjOU1yL/wCJoAFfxnsj8nwXZJNkAtPqqFBjvhVJ/Kq9tpHj53uGGj+FbYTNvxJdzSYP4J7CppfG3xCijJb4YyM2ONmsRH/2Wobfxn8TbiRVT4bQwqR1m1dBz68L0oAzNR+HvjfVLl5rm68KQGSMRsIoZm4DBsc47irNp8MPEvnTyXPiPTI2uCPNeDTSxwABhdz4A4rXtNQ+LF0W8zQ/CtgM8eddyy4H/ABz+lXp7b4lTqETUvC9ruHMiWszlOewZufxxQBjWvwct2gSDVPEmr3cKKEEcIjtxgdvkXP61uqngz4R+GrmXdbaXZkmWQvIWmuHxgdSWduwqX/hE9avIVXWfGWqOdoDCwiitAT35Ck/rSaV8MfCWnXgvDpKX1+Du+1ahI11IDnOQZCcc+mKAPOvh78OZ/GGp6h4z8apcQxavdC7g0h/lCxqMRmXuTgA7enNewWGlww67PcxwCNIoEt4sdB1LYH/AHyPwrZoAxQAwRgTGT+IqF/AZ/xp9FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBBNaRSkErhh3HFUrvSIpg6qsYRlIYMuc56j6GtSigDz3SvBUeh3s8tvGzwPK7JGcYj3A/d9vaok8KR2qXL20axpI5l2lzjcw65/wr0emtGrHJHPqOKAOW0vT99zGqlo440UYI68Hpn/ADg1i+KLNRJZh5hE0hc7pTwQCOB6dRiu8ksoHcNsIYDGQSO+apXug2d3t8xWAXOAO2fr9KAPlr4w+GJHjzDExUqyO2c7iT6+1Z/ww1OTVdGFpdSsl3a5t5l7/LwP0xX0l4i8IrdotqDvtXGAjdiK+efiD4Qv/h14oGu6ePO0yYr9rhV+WP8AeA7n2oA2PFHgCTxHaSKEBcfOpA5OK8i1L4Sa5Zyu3kNJECezZP4Yr69+GevaF4k02OewvLd51+/FuCupxjlDyK6nULrRdPVn1C8sYFbnMkgUnj680AfBX/CAawLbKaXdSzbgCBGfr6V0Wk/C3xBLtlazhtIol3NLM+AB7j2FfVF/4hudSjMXgrw1JqrHKG7ul+y2q9s7n+Z/+AqfrVaz+Fs2rXSXXjvVf7RjU7l0qyQwWan0bndL0/iIHtQB538HfhhZaxqB1HUpLnUNOtyQJeYoLhgeiYwXUHOT09M19H2dnbWUCw2cEUES9EjUKP0qSCKOCFIYI0jijUKiIAFUDoAB0FPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs/V9SbTolZLC+vXY48u1jDEe5LED9a0KKAOJuL7xxqwaPTdK0/QYj/wAvOoTi5kx7RR/Ln6vWbL8LjrRLeN/E2sa8jNuNosn2S1+nlx4JH1Y16RRQBm6JoWlaFbC30bTrSxhAxtt4lT88da0qKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCOeIyxlBJJHkY3IQCKw73w5PdY/4qLXITzzDJEv/ALTroKKAOOuPANtdvuvte8SXA67TqLRgHGMgIFxUdv8AC7wdFcRTyaOt3PHyr3k8twc/SRiK7WigDEh8J+HoZWlj0PTBKxyX+zIWP44zV6y0rTrFt1lYWlu3rDCqfyFXaKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following cryoretinopexy, an exoplant is sutured to the outside of the sclera that indents the wall of the eye and closes the retinal breaks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wilkinson CP, Rice TA. Mitchel's Retinal Detachment, 2nd ed, Mosby-Year Book, Inc., Louis 1997. Copyright &copy; Charles P Wilkinson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3474=[""].join("\n");
var outline_f3_25_3474=null;
var title_f3_25_3475="MRI Dementia with Lewy bodies versus Alzheimer disease";
var content_f3_25_3475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Dementia with Lewy bodies versus Alzheimer disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thin section coronal T1 weighted images from a 61-year-old male with pathologically proven Dementia with Lewy bodies (A) and a 69-year-old male with Alzheimer disease (B). There is relative preservation of the medial temporal lobes and hippocampal structures in the DLB patient as compared with the AD patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3475=[""].join("\n");
var outline_f3_25_3475=null;
var title_f3_25_3476="Mitral valve prolapse syndrome";
var content_f3_25_3476=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mitral valve prolapse syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3476/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3476/contributors\">",
"     Matthew J Sorrentino, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3476/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3476/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3476/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3476/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/25/3476/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve prolapse (MVP) is associated with a wide variety of clinical features. There are potentially serious arrhythmic and nonarrhythmic complications such as sudden death and infective endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a variety of more nonspecific complaints have been associated with MVP. Atypical or non-anginal chest pain is the most common symptom attributed to MVP. Other manifestations may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Exercise intolerance",
"     </li>",
"     <li>",
"      Dizziness or syncope",
"     </li>",
"     <li>",
"      Panic and anxiety disorders",
"     </li>",
"     <li>",
"      Numbness or tingling",
"     </li>",
"     <li>",
"      Skeletal abnormalities",
"     </li>",
"     <li>",
"      Abnormal resting and exercise electrocardiograms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any combination of these symptoms and signs plus the typical auscultatory features of MVP have been defined as the mitral valve prolapse syndrome. This topic will review the validity, pathophysiology, and treatment of this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VALIDITY OF THE SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large number of symptoms directly attributed to MVP may be coincidental. The questionable link between MVP and the above list of nonspecific symptoms may have originated because of inaccurate study designs and selection bias. As an example, many studies may not have had well matched control groups, which is essential because many of the symptoms attributed to MVP commonly occur in the general population. In addition, studies based at tertiary care centers may have attracted potentially more symptomatic patients than those who seek medical attention at smaller medical centers. Thus, trials performed at these centers may have overestimated the true prevalence of symptomatic patients with MVP.",
"   </p>",
"   <p>",
"    Appropriately controlled clinical studies suggest that patients with MVP and control subjects are equally symptomatic. Support for this comes from a report of the Framingham Heart Study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3476/abstract/1\">",
"     1",
"    </a>",
"    ]. Eighty-four patients with MVP based upon current two-dimensional echocardiographic criteria were compared to 3403 control subjects without MVP; chest pain, dyspnea, syncope, congestive heart failure, atrial fibrillation and ECG abnormalities were equally prevalent in affected patients and matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3476/abstract/1\">",
"     1",
"    </a>",
"    ]. Two findings that were more common in MVP were an asthenic body habitus and a greater degree of mitral regurgitation.",
"   </p>",
"   <p>",
"    It is possible, however, that autonomic and neuroendocrine dysfunction found in some patients with MVP may underlie some of the symptoms associated with this disorder. One study, for example, compared the clinical symptoms in",
"    <strong>",
"     affected",
"    </strong>",
"    (ie, with MVP) first degree relatives of patients with MVP with those of",
"    <strong>",
"     unaffected",
"    </strong>",
"    relatives and spouses in an attempt to overcome selection bias [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3476/abstract/2\">",
"     2",
"    </a>",
"    ]. Eighty-one first degree relatives had MVP as determined by echocardiography while 172 relatives and 60 spouses were not affected. Palpitations, decreased systolic pressure, low body weight, and thoracic bony abnormalities were more common in patients with MVP. Chest pain was also more frequent, but only after addition of the initial referral group. This finding supports the hypothesis that symptomatic patients may be more likely to seek medical attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms attributed to MVP cannot clearly be explained by the degree of prolapse or mitral regurgitation. However, autonomic or neuroendocrine dysfunction has been suggested as a possible cause of the nonspecific symptoms in many patients with MVP. Patients with MVP tend to exhibit the following findings when compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3476/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated urine and plasma catecholamine levels",
"     </li>",
"     <li>",
"      An exaggerated heart rate response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"     </li>",
"     <li>",
"      A less than expected bradycardic response to the dive reflex",
"     </li>",
"     <li>",
"      The reproduction of symptoms with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      infusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specificity of these findings for MVP is uncertain. One study found a series of abnormalities in patients with symptoms of autonomic dysfunction which did not correlate with the presence or absence of MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3476/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between panic disorder and MVP has also been suggested by several studies including a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3476/abstract/6\">",
"     6",
"    </a>",
"    ]. However, these studies have been criticized because of inconsistencies in the diagnostic criteria used for both panic disorder and MVP, and the use of imperfectly matched controls. In addition, panic disorder and MVP are both common illnesses with similar age and gender distributions, suggesting that their association may only be a coincidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptomatic relief of patients with MVP may require both general and pharmacologic measures. Reassurance about the benign nature of the disorder is often adequate to reduce the severity of symptoms in many patients. Many patients also appear to benefit from a change in lifestyle, including aerobic exercise training, the avoidance of stimulants (caffeine), alcohol and undue fatigue, and a reduction in stress. One study, for example, evaluated the efficacy of aerobic exercise (three times per week for 12 weeks) in 32 symptomatic women with MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3476/abstract/7\">",
"     7",
"    </a>",
"    ]. Compared with control subjects, the exercise group showed a decrease in anxiety scores, an increase in general well-being, and a decline in the frequency of chest pain, fatigue, dizziness, and mood swings.",
"   </p>",
"   <p>",
"    It is important that a lifestyle modification program be started gradually and consistently. A response to this regimen may take several weeks and frequent encouragement is often required.",
"   </p>",
"   <p>",
"    Magnesium supplementation may benefit a subset of patients with symptoms and magnesium deficiency. One study of 141 patients with MVP found a significant number of MVP patients had a low serum magnesium compared to 40 healthy controls (60 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3476/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients with low serum magnesium received five weeks of magnesium supplementation or placebo; magnesium supplementation resulted in a significant reduction in weakness, chest pain, palpitations and anxiety. A decrease in the mean daily excretion of norepinephrine was noted in the magnesium-treated group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest pain attributed to MVP is usually atypical and easily distinguishable from angina. The pain is generally mild but can be disabling and recurrent.",
"   </p>",
"   <p>",
"    Patients with chest pain and MVP should be evaluated in the same manner as any patient with chest discomfort. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .) If no cause is found, we do not recommend the use of beta blockers, because there is no evidence that they are effective. However, a modest change in lifestyle including the initiation of an exercise program may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3476/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with symptoms diagnostic of anxiety disorder, panic disorder, or depression should be treated for these illnesses with the same indications as those without MVP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Palpitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpitations are a common presenting complaint in MVP. The evaluation of patients with symptomatic palpitations is similar to that in patients without MVP. Palpitations are often associated with ventricular premature beats, but supraventricular arrhythmias can also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .) In addition, palpitations may be reported by patients at a time when an arrhythmia is absent on continuous ambulatory recording. Thus, the presence of an arrhythmia should be confirmed before beginning antiarrhythmic therapy. Beta blockers may be helpful in patients who present with hyperadrenergic symptoms such as tachycardia, palpitations, nervousness, and an exaggerated heart rate response to exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hyperventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of hyperventilation, including dyspnea, dizziness, numbness and tingling, are common in MVP. Objective exercise testing in these symptomatic patients is usually normal and the symptoms frequently respond to lifestyle modifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=see_link\">",
"       \"Patient information: Mitral valve prolapse (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H700708\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical or non-anginal chest pain is the most common symptom attributed to mitral valve prolapse (MVP). Other manifestations may include palpitations, dyspnea, exercise intolerance, dizziness or syncope, and panic and anxiety disorders. Any combination of these symptoms and signs plus the typical auscultatory features of MVP have been defined as the mitral valve prolapse syndrome.",
"     </li>",
"     <li>",
"      The large number of symptoms directly attributed to MVP may be coincidental. It is possible, however, that autonomic and neuroendocrine dysfunction found in some patients with MVP may underlie some of the symptoms associated with this disorder.",
"     </li>",
"     <li>",
"      Reassurance about the benign nature of MVP syndrome is often adequate to reduce the severity of symptoms in many patients. Many patients also appear to benefit from a change in lifestyle, including aerobic exercise training, the avoidance of stimulants (caffeine), alcohol and undue fatigue, and a reduction in stress.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3476/abstract/1\">",
"      Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3476/abstract/2\">",
"      Devereux RB, Kramer-Fox R, Brown WT, et al. Relation between clinical features of the mitral prolapse syndrome and echocardiographically documented mitral valve prolapse. J Am Coll Cardiol 1986; 8:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3476/abstract/3\">",
"      Gaffney FA, Karlsson ES, Campbell W, et al. Autonomic dysfunction in women with mitral valve prolapse syndrome. Circulation 1979; 59:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3476/abstract/4\">",
"      Boudoulas H, Kolibash AJ Jr, Baker P, et al. Mitral valve prolapse and the mitral valve prolapse syndrome: a diagnostic classification and pathogenesis of symptoms. Am Heart J 1989; 118:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3476/abstract/5\">",
"      Taylor AA, Davies AO, Mares A, et al. Spectrum of dysautonomia in mitral valvular prolapse. Am J Med 1989; 86:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3476/abstract/6\">",
"      Katerndahl DA. Panic and prolapse. Meta-analysis. J Nerv Ment Dis 1993; 181:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3476/abstract/7\">",
"      Scordo KA. Effects of aerobic exercise training on symptomatic women with mitral valve prolapse. Am J Cardiol 1991; 67:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3476/abstract/8\">",
"      Lichodziejewska B, K��o�� J, Rezler J, et al. Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation. Am J Cardiol 1997; 79:768.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8168 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3476=[""].join("\n");
var outline_f3_25_3476=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H700708\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VALIDITY OF THE SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Palpitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hyperventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H700708\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=related_link\">",
"      Patient information: Mitral valve prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_25_3477="Trauma management: Unique pediatric considerations";
var content_f3_25_3477=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trauma management: Unique pediatric considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3477/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3477/contributors\">",
"     Lois K Lee, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3477/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3477/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3477/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3477/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3477/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/25/3477/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children have unique anatomy and physiology compared with adults, which must be taken into consideration when managing pediatric trauma patients. This review will cover specific anatomical and physiologic differences between children and adults that affect medical care. The approach to the injured child is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PEDIATRIC ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several features of the airway in infants and children can make airway management challenging in patients with major trauma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small oral cavities and relatively large tongues and tonsils predispose to airway obstruction, especially in semiconscious or comatose patients.",
"     </li>",
"     <li>",
"      The relatively large occiput in the infant or child naturally flexes the neck in the supine position, causing airway obstruction as well as potentially exacerbating any unstable cervical spine injury.",
"     </li>",
"     <li>",
"      The larynx is more cephalad and anterior in the neck, making proper visualization during endotracheal intubation more difficult [",
"      <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/1\">",
"       1",
"      </a>",
"      ]. Other factors to consider include the short trachea, the U-shaped, floppy epiglottis in infants and young children, and the maximal anatomic narrowing that occurs at the cricoid ring [",
"      <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A narrow tracheal diameter, a small distance between the tracheal rings, and a cricothyroid membrane that is not easily palpable combine to make needle cricothyroidotomy (to provide percutaneous transtracheal ventilation) a technically challenging option in infants and children [",
"      <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"       \"The difficult pediatric airway\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16441?source=see_link\">",
"       \"Needle cricothyroidotomy with percutaneous transtracheal ventilation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With the short trachea (5 cm long in infants, 7 cm long in 18-month-old children), there is a higher risk for initial right mainstem bronchus intubation or subsequent accidental tube dislodgement with any motion of the head [",
"      <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these factors make securing and maintaining the airway of pediatric trauma patients more difficult than in adults, especially in children &lt;3 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Head",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and young children &lt;8 years of age have heads that are disproportionately large relative to the rest of their body. As a result, head trauma is commonly present following blunt injury and is the leading cause of mortality in pediatric trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Brain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants have skulls with open sutures, and their brains have a larger subarachnoid space and increased extracellular space. As a result, they tend to tolerate an expanding intracranial hematoma better than older children or adults.",
"   </p>",
"   <p>",
"    However, the infant brain is less myelinated and the cranium thinner and less protective; therefore, mild forces may still result in significant parenchymal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, the possibility of abusive head injury in infants and young children must be considered and may present with abrupt altered mental status and severe injury by head CT without a plausible mechanism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Spinal cord/spine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young children are at increased risk for spinal cord injury without radiographic abnormality (SCIWORA) because of anatomic flexibility that allows the cervical spine to stretch farther without injury than the spinal cord can tolerate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children have a compliant chest wall, so rib fractures are less common, and pulmonary injury (eg, pulmonary contusion) is often present without bony disruption. In addition, because of their mobile mediastinal structures, children are more likely to develop tension pneumothoraces than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver and spleen in infants and toddlers are less protected by the rib cage and are more prone to direct injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Musculoskeletal system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children have immature bones, which are more pliable and are prone to fractures of the physes (growth plates) (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"     figure 1",
"    </a>",
"    ). Blood loss associated with an isolated fracture, including femur fracture, is less than that of adults and by itself should not cause hemodynamic instability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/1-4,6,7\">",
"     1-4,6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link\">",
"     \"General principles of fracture management: Fracture patterns and description in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vascular system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular access for fluid resuscitation is often more difficult to achieve in children than in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PEDIATRIC PHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal vital signs change with age in children (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). In general, heart rate and respiratory are higher than in adults and blood pressure is lower. The 5th percentile systolic blood pressure for age can be approximated by the following formula for children 1 to 10 years of age:",
"   </p>",
"   <p>",
"    &nbsp;Systolic pressure (5th percentile) = 70 mmHg + 2 X (age in years)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children are prone to hypothermia and insensible fluid losses because of their large body surface area to weight ratio and higher metabolic rate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/8\">",
"     8",
"    </a>",
"    ]. Hypothermia can complicate an already critical situation as it may worsen metabolic acidosis and exert a negative inotropic effect on the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Breathing and ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxia is the most common cause of cardiac arrest in children. Adequate oxygenation is essential, as is adequate ventilation to maintain acid-base balance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/2\">",
"     2",
"    </a>",
"    ]. Because of limited functional residual capacity and increased oxygen utilization relative to adults, infants and children become hypoxemic much more quickly when ventilation is inadequate. Infants and young children also have smaller tidal volumes (6 to 8",
"    <span class=\"nowrap\">",
"     mL/kg),",
"    </span>",
"    and are at greater risk for iatrogenic barotrauma with overly aggressive artificial ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia and poor skin perfusion are the initial signs of circulatory failure in children (",
"    <a class=\"graphic graphic_table graphicRef68694 \" href=\"UTD.htm?33/47/34556\">",
"     table 2",
"    </a>",
"    ). Their increased physiologic reserve allows children to maintain their blood pressure despite a loss of 30 to 45 percent of total blood volume. Thus, hypotension with uncompensated shock is a late and sudden finding that requires an immediate response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In infants, uncompensated shock with hypotension in the early stages is accompanied by tachycardia, which may change to bradycardia if blood loss continues unchecked [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3477/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the priorities and organization of trauma care for children are the same as for adults, unique pediatric anatomy and physiology create specific challenges in assessment and management:",
"     </li>",
"     <li>",
"      Securing and maintaining the airway of a pediatric trauma patient may be more difficult, especially in children &lt;3 years of age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children are more prone to develop tension pneumothorax and pulmonary contusion. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chest'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal vital signs change with age in children (",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). In general, heart and respiratory rates are higher than in adults and blood pressure is lower. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vital signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and children become hypoxemic when ventilation is inadequate much more quickly than adults. Infants and young children also have smaller tidal volumes (6 to 8",
"      <span class=\"nowrap\">",
"       mL/kg),",
"      </span>",
"      and are at greater risk for iatrogenic barotrauma with overly aggressive artificial ventilation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Breathing and ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children are prone to hypothermia and insensible fluid losses. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tachycardia and poor skin perfusion are the initial signs of circulatory failure in children (",
"      <a class=\"graphic graphic_table graphicRef68694 \" href=\"UTD.htm?33/47/34556\">",
"       table 2",
"      </a>",
"      ). Children can maintain their blood pressure despite a loss of 30 to 45 percent of total blood volume. Thus, hypotension with uncompensated shock is a late and sudden finding that requires an immediate medical response. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infants, uncompensated shock with hypotension in the early stages is also accompanied by tachycardia, which may change to bradycardia if blood loss continues unchecked. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular access for fluid resuscitation is often more difficult to achieve. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Vascular system'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3477/abstract/1\">",
"      Lloyd-Thomas AR. ABC of major trauma. Paediatric trauma: primary survey and resuscitation--I. BMJ 1990; 301:334.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma. Advanced Trauma Life Support for Doctors, American College of Surgeons, Chicago 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3477/abstract/3\">",
"      Schafermeyer R. Pediatric trauma. Emerg Med Clin North Am 1993; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3477/abstract/4\">",
"      Jaffe D, Wesson D. Emergency management of blunt trauma in children. N Engl J Med 1991; 324:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3477/abstract/5\">",
"      Dormans JP. Evaluation of children with suspected cervical spine injury. J Bone Joint Surg Am 2002; 84-A:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3477/abstract/6\">",
"      Ciarallo L, Fleisher G. Femoral fractures: are children at risk for significant blood loss? Pediatr Emerg Care 1996; 12:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3477/abstract/7\">",
"      Kapklein MJ, Mahadeo R. Pediatric trauma. Mt Sinai J Med 1997; 64:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3477/abstract/8\">",
"      Cantor RM, Leaming JM. Evaluation and management of pediatric major trauma. Emerg Med Clin North Am 1998; 16:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3477/abstract/9\">",
"      Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6533 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3477=[""].join("\n");
var outline_f3_25_3477=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PEDIATRIC ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Head",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Brain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Spinal cord/spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Musculoskeletal system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vascular system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PEDIATRIC PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vital signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Breathing and ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6533\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6533|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21361\" title=\"figure 1\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6533|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/37/28252\" title=\"table 1\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/47/34556\" title=\"table 2\">",
"      Classification of pediatric hemorrhage shock",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16441?source=related_link\">",
"      Needle cricothyroidotomy with percutaneous transtracheal ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_25_3478="Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Pediatric drug information";
var content_f3_25_3478=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?17/57/18326?source=see_link\">",
"    see \"Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/34/22049?source=see_link\">",
"    see \"Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pediarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pediarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/57/18326?source=see_link\">",
"      see \"Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Infants &ge;6 weeks and Children &lt;7 years: 0.5 mL per dose; preterm infants should be vaccinated according to their chronological age from birth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recommended schedule: 3 doses repeated in 6- to 8-week intervals (preferably 8-week intervals); vaccination usually begins at 2 months, but may be started as early as 6 weeks of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Infants &ge;6 weeks and children previously vaccinated with one or more components of this combination vaccine, and who are also scheduled to receive all vaccine components, may use Pediarix&trade; to complete the series.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pediarix&reg;: Diphtheria toxoid 25 Lf, tetanus toxoid 10 Lf, acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutin 25 mcg, pertactin 8 mcg, HBsAg 10 mcg, type 1 poliovirus 40 D antigen units, type 2 poliovirus 8 D antigen units and type 3 poliovirus 32 D antigen units] per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate (trace amounts), polymyxin B (trace amounts), polysorbate 80, and yeast protein &le;5%; may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well; administer I.M. in either the anterolateral aspect of the thigh or arm;",
"     <b>",
"      not for I.V. or SubQ administration",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. law requires that the date of administration, name of the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F161326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with other vaccines or injections.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Discard if frozen.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination vaccine for the active immunization against diphtheria, tetanus, pertussis, hepatitis B virus (all known subtypes), and poliomyelitis (caused by poliovirus types 1, 2, and 3) (FDA approved in ages 6 weeks through 6 years)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F161325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adverse events reported within 4 days of vaccination at 2-, 4-, and 6 months of age in patients given Pediarix&reg; concomitantly with Hib conjugate vaccine and PCV7 vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness, fever, irritability/fussiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Loss of appetite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Pain, redness, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Additional and postmarketing events: Anaphylactic/anaphylactoid reaction, angioedema, anorexia, apnea, arthus-type hypersensitivity  reactions, brachial neuritis, bulging fontanelle, consciousness depressed, cough, cranial mononeuropathy, crying, cyanosis, demyelinating disease, diarrhea, dyspnea, encephalitis, erythema, fatigue, febrile convulsion, Guillain-Barr&eacute; syndrome, hypersensitivity reaction, hypotonia, hypotonic-hyporesposnive episode, injection site reactions (cellulitis, induration, itching, nodule, warmth, vesicles), insomnia, lethargy, limb pain, limb swelling, liver function test abnormalities, nervousness, pallor, peripheral mononeuropathy, petechiae, rash, restlessness, screaming, seizure, SIDS, somnolence, upper respiratory tract infection, urticaria, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component including yeast, neomycin, and polymyxin B; encephalopathy occurring within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another cause; progressive neurological disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy (pertussis vaccine should be withheld until the clinical condition has stabilized); defer vaccination for persons with acute febrile illness until recovery; children &ge;7 years and adults (formulation without pertussis is indicated for use in these patients)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with coagulation disorders including thrombocytopenia, due to an increased risk for bleeding following I.M. administration; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactic/anaphylactoid reaction should be available during vaccine use. Subsequent vaccination with a pertussis-containing vaccine should be carefully considered if the following reactions occur with a temporal relationship to a previous dose: Temperature &ge;40.5&deg;C (105&deg;F) within 48 hours, not attributable to another identifiable cause, collapse, or shock-like state (hypotonic-hyporesponsive episode) within 48 hours, persistent crying lasting &ge;3 hours within 48 hours, or convulsions with or without fever, occurring within 3 days. Guillain-Barr&eacute; syndrome occurring within 6 weeks of vaccines containing tetanus toxoid has been reported; due to a higher rate of fever with this combination formulation than with individual vaccines, antipyretic prophylaxis at the time of and following vaccination may be considered for patients at high risk for seizures. Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F161301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted; not indicated for women of childbearing age.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10184964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes active immunity to diphtheria, tetanus, pertussis, hepatitis B and poliovirus (types 1, 2, and 3) by inducing production of specific antibodies and antitoxins.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/34/22049?source=see_link\">",
"      see \"Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause increased sleeping, restlessness, fussiness, decreased appetite, or fever (use antipyretic if directed by healthcare provider). May cause some redness, pain, or swelling at injection site; consult healthcare provider if excessive or persistent. Notify healthcare provider immediately of any excessive or persistent reactions (eg, fever &gt;105&deg;F within 48 hours, inconsolable crying that occurs within 48 hours and lasts 3 hours, seizures that occur within 3 days).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1058047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains the following three pertussis antigens: Inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin. Contains the same diphtheria and tetanus toxoids and pertussis antigens found in Infanrix&reg;. Contains the same hepatitis B surface antigen (HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag) found in Engerix-B&reg; (recombinant vaccine). Thimerosal is used during manufacturing, but removed to less than detectable levels in the final suspension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3478/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3478/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3478/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-15):1-48. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3478/abstract-text/17136024/pubmed\" id=\"17136024\" target=\"_blank\">",
"        17136024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination &minus; United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3478/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3478/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3478/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12729 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3478=[""].join("\n");
var outline_f3_25_3478=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934399\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058040\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058033\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161293\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161282\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058044\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161326\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058036\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058043\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161325\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058046\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058032\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058031\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299221\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161288\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161290\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161301\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10184964\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058030\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058038\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058047\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12729\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12729|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/57/18326?source=related_link\">",
"      Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/34/22049?source=related_link\">",
"      Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_25_3479="Vitamin K (phytonadione): Drug information";
var content_f3_25_3479=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin K (phytonadione): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/4/38980?source=see_link\">",
"    see \"Vitamin K (phytonadione): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/21/15701?source=see_link\">",
"    see \"Vitamin K (phytonadione): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mephyton&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AquaMEPHYTON&reg;;",
"     </li>",
"     <li>",
"      Konakion;",
"     </li>",
"     <li>",
"      Mephyton&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F209803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin, Fat Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F209763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     According to the manufacturer, SubQ is the preferred parenteral route; I.M. route should be avoided due to the risk of hematoma formation; I.V. route should be restricted for emergency use only. The American College of Chest Physicians (ACCP) recommends the I.V. route in patients with major bleeding secondary to use of vitamin K antagonists (VKAs).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral: Males: 120",
"     <b>",
"      mcg",
"     </b>",
"     /day; Females: 90",
"     <b>",
"      mcg",
"     </b>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypoprothrombinemia due to drugs (other than coumarin derivatives) or factors limiting absorption or synthesis:",
"     </b>",
"     Oral, SubQ, I.M., I.V.: Initial: 2.5-25 mg (rarely up to 50 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin K deficiency (supratherapeutic INR) secondary to VKAs (eg, warfarin) (unlabeled dose):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      If INR above therapeutic range to &lt;4.5 (no evidence of bleeding):",
"     </i>",
"     Lower or hold next VKA dose and monitor frequently; when INR approaches desired range, resume VKA dosing with a lower dose (Patriquin, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      If INR 4.5-10 (no evidence of bleeding):",
"     </i>",
"     The 2012 ACCP guidelines recommend against routine phytonadione (aka, vitamin K) administration in this setting (Guyatt, 2012). Previously, the 2008 ACCP guidelines recommended if no risk factors for bleeding exist, to omit next 1 or 2 VKA doses, monitor INR more frequently, and resume with an appropriately adjusted VKA dose when INR in desired range; may consider administering vitamin K orally 1-2.5 mg if other risk factors for bleeding exist (Hirsh, 2008). Others have recommended consideration of vitamin K 1 mg orally or 0.5 mg I.V. (Patriquin, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      If INR &gt;10 (no evidence of bleeding):",
"     </i>",
"     The 2012 ACCP guidelines recommend administration of oral vitamin K (dose not specified) in this setting (Guyatt, 2012). Previously, the 2008 ACCP guidelines recommended to hold warfarin, administer vitamin K orally 2.5-5 mg, expect INR to be reduced within 24-48 hours, monitor INR more frequently and give additional vitamin K at an appropriate dose if necessary; resume warfarin at an appropriately adjusted dose when INR is in desired range (Hirsh, 2008). Others have recommended consideration of vitamin K 2-2.5 mg orally or 0.5-1 mg I.V. (Patriquin, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      If minor bleeding at any INR elevation:",
"     </i>",
"     Hold warfarin, may administer vitamin K orally 2.5-5 mg, monitor INR more frequently, may repeat dose after 24 hours if INR correction incomplete; resume warfarin at an appropriately adjusted dose when INR is in desired range (Patriquin, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      If major bleeding at any INR elevation:",
"     </i>",
"     The 2012 ACCP guidelines recommend administration of four-factor prothrombin complex concentrate (PCC) and I.V. vitamin K 5-10 mg in this setting (Guyatt, 2012); however, in the U.S., the available PCCs (Bebulin&reg;VH and Profilnine&reg; SD) are",
"     <b>",
"      three",
"     </b>",
"     -factor PCCs and do not contain adequate levels of factor VII. Four-factor PCCs include Beriplex&reg; P/N, Cofact&reg;, Konyne&reg;, or Octaplex&reg; all of which are",
"     <b>",
"      not",
"     </b>",
"     available in the U.S. Previously, the 2008 ACCP guidelines recommended to hold warfarin, administer vitamin K 10 mg by slow I.V. infusion and supplement with PCC depending on the urgency of the situation; I.V. vitamin K may be repeated every 12 hours (Hirsh, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use of high doses of vitamin K (eg, 10-15 mg) may cause warfarin resistance for &ge;1 week. During this period of resistance, heparin or low-molecular-weight heparin (LMWH) may be given until INR responds (Ansell, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preprocedural/surgical INR normalization in patients receiving warfarin (routine use):",
"     </b>",
"     Oral: 1-2.5 mg once administered on the day before surgery; recheck INR on day of procedure/surgery (Douketis, 2012). Others have recommended the use of vitamin K 1 mg orally for mild INR elevations (ie, INR 3.0-4.5) (Patriquin, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F209784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/21/15701?source=see_link\">",
"      see \"Vitamin K (phytonadione): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     According to the manufacturer, SubQ is the preferred parenteral route; I.M. route should be avoided due to the risk of hematoma formation; I.V. route should be restricted for emergency use only. The American College of Chest Physicians (ACCP) recommends the I.V. route in patients with major bleeding secondary to use of vitamin K antagonists (VKAs).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adequate intake (AI): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0-6 months: 2",
"     <b>",
"      mcg",
"     </b>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7-12 months: 2.5",
"     <b>",
"      mcg",
"     </b>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 years: 30",
"     <b>",
"      mcg",
"     </b>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-8 years: 55",
"     <b>",
"      mcg",
"     </b>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-13 years: 60",
"     <b>",
"      mcg",
"     </b>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     14-18 years: 75",
"     <b>",
"      mcg",
"     </b>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hemorrhagic disease of the newborn:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: I.M.: 0.5-1 mg within 1 hour of birth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: I.M., SubQ: 1 mg/dose/day; higher doses may be necessary if mother has been receiving oral anticoagulants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin K deficiency (supratherapeutic INR) secondary to vitamin K antagonists (VKAs) (eg, warfarin) (unlabeled use):",
"     </b>",
"     Infants and Children:",
"     <i>",
"      Excessively prolonged INR (usually INR &gt;8; no significant bleeding):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Limited data available: I.V.: 0.03 mg/kg/dose; maximum dose: 1 mg (Bolton-Maggs, 2002); if significant bleeding, consider use of fresh frozen plasma, prothrombin complex concentrates, or recombinant factor VIIa (Monagle, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F209764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, aqueous colloidal: 1 mg/0.5 mL (0.5 mL) [contains benzyl alcohol, polyoxyethylated castor oil]; 10 mg/mL (1 mL) [contains benzyl alcohol, polyoxyethylated castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, aqueous colloidal [preservative free]: 1 mg/0.5 mL (0.5 mL) [contains polysorbate 80, propylene glycol 10.4 mg/0.5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mephyton&reg;: 5 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F209744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. administration: Infuse slowly; rate of infusion should not exceed 1 mg/minute (3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /minute in children and infants). Alternatively, dilute dose in a minimum of 50 mL of compatible solution and administer using an infusion pump over at least 20 minutes (Ageno, 2012). The injectable route should be used only if the oral route is not feasible or there is a greater urgency to reverse anticoagulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Crowther, 2000; O&rsquo;Connor, 1986).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F209742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of hypoprothrombinemia caused by vitamin K antagonist (VKA)-induced (eg, warfarin-induced) or other drug-induced vitamin K deficiency, altered activity, or altered metabolism; hypoprothrombinemia caused by malabsorption or inability to synthesize vitamin K; prophylaxis and treatment of hemorrhagic disease of the newborn",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5263531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypoprothrombinemia caused by long-acting anticoagulant rodenticides (LAARs)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mephyton&reg; may be confused with melphalan, methadone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F209802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Cyanosis, flushing, hyper-/hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Erythematous skin eruptions, pruritus, scleroderma-like lesions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hyperbilirubinemia (newborn; greater than recommended doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abnormal taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Diaphoresis, hypersensitivity reactions, nonimmunologic anaphylaxis (formerly known as anaphylactoid reaction), sweating",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F209748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phytonadione or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F209731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe reactions resembling hypersensitivity reactions (eg, anaphylaxis) have occurred rarely during or immediately after I.V. administration (even with proper dilution and rate of administration); some patients had no previous exposure to phytonadione.",
"     </b>",
"     Anaphylactoid reactions typically occurred when patients received large I.V. doses administered rapidly with formulations containing polyethoxylated castor oil; proper dosing, dilution, and administration will minimize risk (Ageno, 2012; Riegert-Johnson, 2002). Limit I.V. administration to situations where an alternative route of administration is not feasible and the benefit of therapy outweighs the risk of hypersensitivity reactions. Allergic reactions have also occurred with I.M. and SubQ injections, albeit less frequently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulant-induced hypoprothrombinemia: In patients receiving a therapeutic vitamin K antagonist (VKA) (eg, warfarin), administer a dose of phytonadione that  will quickly lower the INR into a safe range without causing resistance to warfarin. High phytonadione doses may lead to warfarin resistance for at least one week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Liver disease induced hypoprothrombinemia: If initial doses do not reverse coagulopathy, then higher doses are unlikely to have any effect.",
"     <b>",
"      Note:",
"     </b>",
"     Ineffective in hereditary hypoprothrombinemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-acting anticoagulant rodenticide (LAAR) ingestion: Patients with LAAR-induced coagulopathy require much larger doses and longer treatment durations (up to months) after exposure compared to that needed to reverse VKA-induced coagulopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Newborns: Use with caution in newborns, especially premature infants; hemolysis, jaundice, and hyperbilirubinemia have been reported with larger than recommended doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Injectable products may contain aluminum; may result in toxic levels following prolonged administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polyethoxylated castor oil (Cremophor&reg; EL): Some dosage forms contain Cremophor&reg; EL which has been associated with anaphylactoid reactions; use these formulations with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: Product may contain polysorbate 80.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate route: Oral administration is the safest and requires the presence of bile salts for absorption. In obstructive jaundice or with biliary fistulas, concurrent administration of bile salts would be necessary for proper absorption. Manufacturers recommend the SubQ route over other parenteral routes, however, SubQ is less predictable when compared to the oral route, and efficacy may be delayed. The American College of Chest Physicians recommends the I.V. route in patients with major bleeding secondary to use of VKAs such as warfarin. The I.V. route should be restricted to emergency situations only where oral phytonadione cannot be used.  Efficacy (eg, control of bleeding, decrease in INR) is delayed regardless of route of administration; patient management may require other treatments in the interim.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Phytonadione. Specifically, mineral oil may decrease the absorption of phytonadione.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Phytonadione may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10916304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F209770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F209750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Phytonadione Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (0.5 mL): $5.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mephyton Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $1146.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F209739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     PT, INR",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F209751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Haemokion (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Hema-K (PH);",
"     </li>",
"     <li>",
"      Kanakion (PT);",
"     </li>",
"     <li>",
"      Kanavit (CZ);",
"     </li>",
"     <li>",
"      Kenadion (IN);",
"     </li>",
"     <li>",
"      Konakion (10 mg) (AE, AU, BG, BH, CY, DE, EC, EG, GB, GH, IE, IL, IQ, IR, IT, JO, KE, KW, LB, LY, NL, OM, QA, SA, SE, SY, TZ, UG, YE, ZM);",
"     </li>",
"     <li>",
"      Konakion (BE, DK, ES, HR, HU, LU, NO);",
"     </li>",
"     <li>",
"      Konakion 10 mg (AT, FI, HN);",
"     </li>",
"     <li>",
"      Konakion MM (MX);",
"     </li>",
"     <li>",
"      Konakion MM Paediatric (BB, BM, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Konakion MM Pediatric (AR, AU, BR, CH, CN, CO, NZ, PE, PK, PY, UY);",
"     </li>",
"     <li>",
"      Neokay (GB);",
"     </li>",
"     <li>",
"      Univitan K1 (HK);",
"     </li>",
"     <li>",
"      Vitacon (PL);",
"     </li>",
"     <li>",
"      Vitak (JP);",
"     </li>",
"     <li>",
"      Vitamin K (HK);",
"     </li>",
"     <li>",
"      Vitamin K1 (KP);",
"     </li>",
"     <li>",
"      Vitamine K!1 Roche (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F209730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes liver synthesis of clotting factors (II, VII, IX, X); however, the exact mechanism as to this stimulation is unknown. Menadiol is a water soluble form of vitamin K; phytonadione has a more rapid and prolonged effect than menadione; menadiol sodium diphosphate (K",
"     <sub>",
"      4",
"     </sub>",
"     ) is half as potent as menadione (K",
"     <sub>",
"      3",
"     </sub>",
"     ).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F209747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Increased coagulation factors: Oral: 6-10 hours; I.V.: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: INR values return to normal: Oral: 24-48 hours; I.V.: 12-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: From intestines in presence of bile; SubQ: Variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ageno W, Gallus AS, Wittkowsky A, et al, &ldquo;Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e44-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/22315269/pubmed\" id=\"22315269\" target=\"_blank\">",
"        22315269",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andersen P and Godal HC, &ldquo;Predictable Reduction in Anticoagulant Activity of Warfarin by Small Amounts of Vitamin K,&rdquo;",
"      <i>",
"       Acta Med Scand",
"      </i>",
"      , 1975, 198:269-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/1189983/pubmed\" id=\"1189983\" target=\"_blank\">",
"        1189983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ansell J, Hirsh J, Hylek E, et al, &ldquo;Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):160-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/18574265/pubmed\" id=\"18574265\" target=\"_blank\">",
"        18574265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barash P, Kitahata LM, and Mandel S, &ldquo;Acute Cardiovascular Collapse After Intravenous Phytonadione,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1976, 55(2):304-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/943998/pubmed\" id=\"943998\" target=\"_blank\">",
"        943998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bolton-Maggs P and Brook L. &ldquo;The Use of Vitamin K for Reversal of Over-Warfarinization In Children,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2002, 118(3):924.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/12181071/pubmed\" id=\"12181071\" target=\"_blank\">",
"        12181071",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bruno GR, Howland MA, McMeeking A, et al, &ldquo;Long-Acting Anticoagulant Overdose: Brodifacoum Kinetics and Optimal Vitamin K Dosing,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2000, 36(3):262-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/10969235/pubmed\" id=\"10969235\" target=\"_blank\">",
"        10969235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chua JD and Friedenberg WR, &ldquo;Superwarfarin Poisoning,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(17):1929-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/9759690/pubmed\" id=\"9759690\" target=\"_blank\">",
"        9759690",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crowther MA, Douketis JD, Schnurr T, et al, \"Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy. A Randomized, Controlled Trial,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2002, 137(4):251-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/12186515/pubmed\" id=\"12186515\" target=\"_blank\">",
"        12186515",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crowther MA, Julian J, McCarty D, et al, &ldquo;Treatment of Warfarin-associated Coagulopathy With Oral Vitamin K: A Randomised Controlled Trial&rdquo;,",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 356(9241):1551-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/11075768/pubmed\" id=\"11075768\" target=\"_blank\">",
"        11075768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Douketis JD, Spyropoulos AC, Spencer FA, et al, &ldquo;Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):326-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/22315266/pubmed\" id=\"22315266\" target=\"_blank\">",
"        22315266",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fiore LD, Scola MA, Cantillon CE, et al, \"Anaphylactoid Reactions to Vitamin K,\"",
"      <i>",
"       J Thromb Thrombolysis",
"      </i>",
"      , 2001, 11(2): 175-83.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gunja N, Coggins A, and Bidny S, &ldquo;Management of Intentional Superwarfarin Poisoning With Long-Term Vitamin K and Brodifacoum Levels,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 2011, 49(5):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/21740137/pubmed\" id=\"21740137\" target=\"_blank\">",
"        21740137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harrell CC and Kline SS, &ldquo;Oral Vitamin K1: An Option to Reduce Warfarin's Activity,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(12):1228-32.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsh J, Guyatt G, Albers GW, et al, &ldquo;Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):71-109.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/18574259/pubmed\" id=\"18574259\" target=\"_blank\">",
"        18574259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hopkins CS, &ldquo;Adverse Reaction to a Cremophor-Containing Preparation of Intravenous Vitamin K,&rdquo;",
"      <i>",
"       Intensive Therapy Clin Monit",
"      </i>",
"      , 1988, 9:254-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martinez-Abad M, Delgado F, Palop V, et al, &ldquo;Vitamin K",
"      <sub>",
"       1",
"      </sub>",
"      and Anaphylactic Shock,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(7-8):871-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chan A, Goldenberg NA, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e737-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/22315277/pubmed\" id=\"22315277\" target=\"_blank\">",
"        22315277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgenstern LB, Hemphill JC, Anderson C, et al, \"Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2010, 41(9):2108-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/20651276/pubmed\" id=\"20651276\" target=\"_blank\">",
"        20651276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Connor ME and Addiego JE, &ldquo;Use of Oral Vitamin K1 to Prevent Hemorrhagic Disease of the Newborn Infant,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1986, 108(4):616-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/3514830/pubmed\" id=\"3514830\" target=\"_blank\">",
"        3514830",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olmos V and Lopez CM, &ldquo;Brodifacoum Poisoning with Toxicokinetic Data,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 2007, 45(5):487-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/17503253/pubmed\" id=\"17503253\" target=\"_blank\">",
"        17503253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patriquin C and Crowther M, &ldquo;Treatment of Warfarin-associated Coagulopathy With Vitamin K,&rdquo;",
"      <i>",
"       Expert Rev Hematol",
"      </i>",
"      , 2011, 4(6):657-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riegert-Johnson DL and Volcheck GW, &ldquo;The Incidence of Anaphylaxis Following Intravenous Phytonadione (Vitamin K1): A 5-year Retrospective Review,&rdquo;",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 2002, 89(4):400-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/12392385/pubmed\" id=\"12392385\" target=\"_blank\">",
"        12392385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shearer MJ, &ldquo;Vitamin K,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8944):229-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/7823718/pubmed\" id=\"7823718\" target=\"_blank\">",
"        7823718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watt BE, Proudfoot AT, Bradberry SM, et al, \"Anticoagulant Rodenticides,\"",
"      <i>",
"       Toxicol Rev",
"      </i>",
"      , 2005, 24(4):259-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/16499407/pubmed\" id=\"16499407\" target=\"_blank\">",
"        16499407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weibert RT, Le DT, Kayser SR, et al, \"Correction of Excessive Anticoagulation With Low-Dose Oral Vitamin K1,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1997, 126(12):959-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3479/abstract-text/9182473/pubmed\" id=\"9182473\" target=\"_blank\">",
"        9182473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9771 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-201.211.0.116-1E8DF5259C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3479=[""].join("\n");
var outline_f3_25_3479=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709210\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209759\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209760\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209803\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209763\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209784\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209764\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209741\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209727\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209744\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209742\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263531\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209808\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209802\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209748\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209731\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299879\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209735\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209737\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10916304\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209770\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209750\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209739\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209751\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209730\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209747\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9771\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9771|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/4/38980?source=related_link\">",
"      Vitamin K (phytonadione): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/21/15701?source=related_link\">",
"      Vitamin K (phytonadione): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_25_3480="Lung transplantation: An overview";
var content_f3_25_3480=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lung transplantation: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3480/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3480/contributors\">",
"     Ramsey R Hachem, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3480/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3480/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3480/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3480/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/25/3480/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past 25 years, lung transplantation has become a viable treatment option for patients with a variety of end-stage lung diseases. The first human lung transplant procedure was performed in 1963, and the recipient survived 18 days, ultimately succumbing to renal failure and malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite the outcome, this demonstrated that lung transplantation was technically feasible and that rejection could be averted with the available immunosuppressive agents, at least for a short time.",
"   </p>",
"   <p>",
"    Over the ensuing 15 years, few lung transplant procedures were performed, and the majority of recipients died perioperatively because of bronchial anastomotic complications. However, in 1981, the first successful heart-lung transplantation was performed for idiopathic pulmonary arterial hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/2\">",
"     2",
"    </a>",
"    ]. This was followed in 1983 by the first successful single lung transplantation for idiopathic pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/3\">",
"     3",
"    </a>",
"    ] and in 1986 by the first double lung transplantation for emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/4\">",
"     4",
"    </a>",
"    ]. These successes were attributed to improved surgical techniques and the advent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Over the following several years, the number of lung transplant procedures performed rapidly increased, and the operation became an accepted treatment for end-stage lung disease.",
"   </p>",
"   <p>",
"    An overview of lung transplantation, including a discussion of outcomes, is presented here. Lung transplantation indications, recipient selection, choice of procedure, post-operative management and complications are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31192?source=see_link\">",
"     \"Lung transplantation: Disease-based choice of procedure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38697?source=see_link\">",
"     \"Lung transplantation: Procedure and postoperative management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12233?source=see_link\">",
"     \"Noninfectious complications following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link\">",
"     \"Evaluation and treatment of acute lung transplant rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 1988 and 1993, the number of lung transplants performed worldwide increased dramatically from 89 to 1160 annually (",
"    <a class=\"graphic graphic_figure graphicRef71574 \" href=\"UTD.htm?14/25/14736\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ]. Between 1993 and 2000, the number of transplants reported to the International Society for Heart and Lung Transplantation (ISHLT) Registry increased modestly as activity appeared to plateau around 2000 procedures annually [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ]. However, there has been a steady growth in the number of procedures performed annually since 2000, and over 3000 transplants were reported in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ]. While part of this increase may be attributable to greater participation in the ISHLT Registry, the rapid rise in activity since 2005 suggests that the lung allocation system implemented in the US in 2005 has increased the number of transplants performed.",
"   </p>",
"   <p>",
"    Donor lung shortage has been the major limiting factor to the number of transplants performed. Lung organ procurement rates from deceased donors have consistently been substantially lower than kidney, liver, and heart procurement rates. Lungs are harvested from only 15 percent of all cadaveric donors, whereas kidneys and livers are harvested from 88 percent and hearts from 30 percent of deceased donors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/6\">",
"     6",
"    </a>",
"    ]. These disparities are likely due to the lung's vulnerability to potential complications that often arise before and after donor brain death such as thoracic trauma, aspiration, ventilator associated lung injury, pneumonia, and neurogenic pulmonary edema. Nonetheless, as many as 40 percent of rejected donor lungs may have been suitable for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, studies suggest that ex vivo lung perfusion and reconditioning may ameliorate lung injury in some cases and allow transplantation from donors previously deemed unsuitable [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Standard and extended criteria for donor lung selection and their impact on short and long-term outcomes are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5640?source=see_link\">",
"     \"Lung transplantation: Donor lung preservation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the early years, single lung transplantation was more frequent than bilateral transplantation. But, while the number of single lung transplants performed annually has remained stable, the number of bilateral transplants has consistently increased and surpassed the number of single lung procedures in 2002 (",
"    <a class=\"graphic graphic_figure graphicRef71574 \" href=\"UTD.htm?14/25/14736\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ]. The choice of procedure and recipient selection are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31192?source=see_link\">",
"     \"Lung transplantation: Disease-based choice of procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common diseases that lead to lung transplant, in order of frequency, are chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, alpha-1 antitrypsin deficiency, and idiopathic pulmonary hypertension (",
"    <a class=\"graphic graphic_figure graphicRef61485 \" href=\"UTD.htm?30/25/31135\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31192?source=see_link\">",
"     \"Lung transplantation: Disease-based choice of procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ORGANIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant organizations and organ allocation policies are influenced by medical, ethical, geographical, and political factors and systems vary from country to country. In the United States, there are three main components of the transplant system: the United Network for Organ Sharing (UNOS), the organ procurement organizations (OPOs), and the transplant centers. Their different responsibilities are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     United Network for Organ Sharing",
"    </span>",
"    &nbsp;&mdash;&nbsp;UNOS is a private, non-profit organization that operates the Organ Procurement and Transplantation Network (OPTN) under a contract with the US Department of Health and Human Services. UNOS develops policies that govern the transplant system with the goal of maximizing the efficient and equitable use of organs. In addition, UNOS maintains data pertaining to the waiting list, organ matching, and transplants. All OPOs and transplant centers must be members of UNOS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Organ Procurement Organizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;OPOs are private, non-profit organizations that recover organs within their geographical territory and allocate them based on UNOS guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lung transplant centers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant centers are the focal point of the transplant system for patients and clinicians. In the United States, many health plans have preferred provider provisions for lung transplantation, and Medicare will only cover the procedure at approved centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LUNG ALLOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since May 2005, the order of patients on the waiting list for lung transplantation has been based on a Lung Allocation Score (LAS) that was developed to address high waiting list mortality and progressively earlier placement of patients on the waiting list [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/6,10,11\">",
"     6,10,11",
"    </a>",
"    ]. Under this system, a waiting list urgency measure (expected number of days lived without a transplant during an additional year on the waitlist) and a post-transplant survival measure (expected number of days lived during the first year post-transplant) are calculated using an individual candidate's clinical and physiological characteristics and the statistical models [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/12\">",
"     12",
"    </a>",
"    ]. The transplant urgency measure is subtracted from the transplant benefit measure to give a raw score, which is normalized to a continuous scale from 0 to 100, giving the final Lung Allocation Score. Higher scores represent higher urgency and greater potential transplant benefit (",
"    <a class=\"graphic graphic_table graphicRef59818 \" href=\"UTD.htm?40/0/40972\">",
"     table 1",
"    </a>",
"    ). Candidates age 0 to 11 are assigned priority based on waiting time.",
"   </p>",
"   <p>",
"    In the years following implementation of the LAS system, wait-list times decreased and the mean LAS score of transplant recipients increased, consistent with a greater urgency for transplantation; the total number of patients transplanted also increased [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/13\">",
"     13",
"    </a>",
"    ]. While the overall one-year survival after transplantation has not changed compared to the era before the LAS system was implemented, recipients with very high LAS scores at transplantation have a significantly higher 90-day and one-year mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with untreatable, advanced stage lung disease are referred to regional transplant centers for evaluation. Transplant centers typically screen the medical records of referred patients before an on-site evaluation is scheduled. The transplant centers thoroughly evaluate patients to determine the appropriateness of placing them on the transplant waiting list and to collect the information from which the Lung Allocation Score is derived. The patient is registered with UNOS and the patient's profile is updated at intervals, usually every six months.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When donor organs become available, the procuring organization contacts UNOS' national transport communications center, UNet",
"      <sup>",
"       &reg;",
"      </sup>",
"      , by telephone or internet access. The UNet",
"      <sup>",
"       &reg;",
"      </sup>",
"      computer system runs",
"      <span class=\"nowrap\">",
"       donor/recipient",
"      </span>",
"      matches based on blood type, size of the organ, and distance between the donor and recipient.",
"     </li>",
"     <li>",
"      UNOS then communicates the ranked match results to the OPOs to contact the transplant centers of the highest ranked patient. Once the organ is accepted, the OPO makes transportation arrangements and the transplant surgery is scheduled.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specifics of donor and recipient lung evaluation, selection, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12425?source=see_link\">",
"     \"Lung transplantation: Deceased donor evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The type of transplant procedure and postoperative management are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31192?source=see_link\">",
"     \"Lung transplantation: Disease-based choice of procedure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38697?source=see_link\">",
"     \"Lung transplantation: Procedure and postoperative management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome after lung transplantation can be assessed based on several different criteria: survival, quality of life, physiologic changes, and cost benefit. Survival is perhaps the most straight forward assessment of outcome, and large registries can easily generate actuarial survival estimates based on multi-center and international data. However, other endpoints such as quality of life offer important insights into the benefits of lung transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Society for Heart and Lung Transplantation (ISHLT) has maintained a registry that has accrued data on more than 23,000 recipients from over a hundred transplant centers worldwide. The Registry has generated survival estimates from these data annually that have become a benchmark for the field [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the 2011 Registry report, the median survival for all adult recipients is 5.5 years, but bilateral lung recipients appear to have a better median survival than single lung recipients (6.8 versus 4.7 years, respectively) (For a figure showing updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled Adult Lung Transplantation Kaplan-Meier Survival at:",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is unclear if this survival advantage is directly related to the choice of operation or to the underlying recipient characteristics that influence this choice. A study that evaluated the impact of recipient age and operation performed on the survival of recipients with pulmonary fibrosis, found that single lung recipients younger than 60 years of age had a survival advantage over bilateral recipients in the same age group [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of underlying diagnosis on survival after transplantation has been evaluated extensively (",
"    <a class=\"graphic graphic_figure graphicRef57297 \" href=\"UTD.htm?38/5/38992\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5,17,18\">",
"     5,17,18",
"    </a>",
"    ]. The underlying diagnosis is often linked to age. In addition, certain diagnoses carry higher risks of operative complications and primary graft dysfunction. Nonetheless, recipients with COPD have the best one year survival, but a lower ten year survival compared to those with CF and alpha-1 antitrypsin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, recipients with IPAH have the lowest one year survival, but their ten year survival approaches those with CF and alpha-1 antitrypsin deficiency. Lastly, those with IPF have lower one- and ten-year survival compared to others.",
"   </p>",
"   <p>",
"    The Registry has also reported that one year survival between the years 2000 and 2009 was significantly better than the two previous eras (1988 to 1994 and 1995 to 1999) (For a figure showing updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled Adult Lung Transplantation Kaplan-Meier Survival by Era (Transplants: January 1988-June 2009) at:",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the improvement in survival between these time periods is less notable at five years, suggesting that management strategies have been more effective at reducing early complications than later ones, possibly due to refinements in surgical techniques and post-operative care. In contrast, survival beyond the first year is primarily affected by chronic rejection and infections, and the incidence of these complications has not changed substantially since 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Causes of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft failure, a form of",
"    <span class=\"nowrap\">",
"     ARDS/diffuse",
"    </span>",
"    alveolar damage (DAD), which occurs in the early hours to days after transplant, is the leading cause of death in the first 30 days after transplantation, accounting for almost 30 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence of early graft failure has varied depending on the definition used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In 2005 the ISHLT proposed a new definition and renamed the syndrome primary graft dysfunction (PGD) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36057?source=see_link\">",
"     \"Primary lung graft dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A grading system for PGD incorporates the",
"    <span class=\"nowrap\">",
"     PaO2/FiO2",
"    </span>",
"    ratio and chest radiograph findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PGD grade 0:",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &gt;300 and no pulmonary edema on chest x-ray",
"     </li>",
"     <li>",
"      PGD grade 1:",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &gt;300 and pulmonary edema on chest x-ray",
"     </li>",
"     <li>",
"      PGD grade 2:",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      = 200 to 300 and pulmonary edema on chest x-ray",
"     </li>",
"     <li>",
"      PGD grade 3:",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &lt;200 and pulmonary edema on chest x-ray",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study validated this proposed definition and found that recipients who were PGD grade 3 at 48 hours after transplant had a 33 percent 90-day mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, a PGD score of 3 at any time in the first 48 hours correlated with increased short and long-term mortality. Furthermore, PGD has been identified as a significant independent risk factor for the development of bronchiolitis obliterans syndrome (BOS), which is a leading cause of late mortality after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic allograft rejection or chronic graft dysfunction, which manifests as BOS, is the leading cause of mortality after the first year, accounting for over 40 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/26\">",
"     26",
"    </a>",
"    ]. This remains the primary obstacle to better long-term outcomes after lung transplantation. The incidence of BOS approaches 50 percent within five years of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/19,27,28\">",
"     19,27,28",
"    </a>",
"    ]. Survival three years after the onset of BOS is only 50 percent, and drops to 30 to 40 percent at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Superimposed infections and malignancies due to immunosuppressive therapy often further complicate the course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious complications remain a leading cause of death at all time points after lung transplantation, accounting for 35 percent of deaths in the first year and 20 percent of deaths thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/19\">",
"     19",
"    </a>",
"    ]. Bacterial bronchitis and pneumonia are most common, but fungi, cytomegalovirus, community acquired respiratory viruses, and mycobacteria all contribute to the overall burden [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignancy accounts for a small percentage of mortality in the first year after transplantation; beyond the first year 7 to 10 percent of all deaths are due to cancer. Nonmelanoma skin cancer is the most prevalent malignancy overall, but posttransplant lymphoproliferative disease (PTLD) is the most common malignancy in the first year after transplant and second most common overall [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"     5",
"    </a>",
"    ]. Other malignancies include colon and breast cancer. A study from Israel found an increased incidence of Kaposi's sarcoma and transitional cell carcinoma of the bladder (4 percent each) in addition to non-melanotic skin cancer and PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the postoperative recovery, most recipients are able to resume an unencumbered lifestyle. Over 80 percent report no activity limitations and almost 40 percent of five-year survivors are working at least part-time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/19\">",
"     19",
"    </a>",
"    ]. Furthermore, multiple studies have documented improved overall and health-related quality of life after lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. One study showed comparable health-related quality of life results between lung transplant recipients and a normative sample of healthy people, with the exception of the social functioning domain [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postoperative complications hamper this improvement in quality of life. Recipients who have developed BOS report more physical restrictions and depressive and anxiety symptoms than those who have not and have decrements in health-related quality of life compared to their pre-BOS evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/36,37,39\">",
"     36,37,39",
"    </a>",
"    ]. Similarly, infections and episodes of acute rejection have a negative impact on health-related quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/37\">",
"     37",
"    </a>",
"    ]. Nonetheless, even if the survival advantage itself is modest, the prospect of improving quality of life and quality-adjusted survival is often the motivation for transplantation for many recipients and almost 90 percent of survivors are satisfied with their decision to have a transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cost and cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relatively small number of studies have examined the cost and the cost-effectiveness of lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. In a study of lung transplantations performed at one center between May 2005 and June 2009, median charges for the transplantation admission were $153,995 for patients with lung allocation scores (LAS) in the three lower quartiles, compared with $276,668 for those with LAS scores in the highest quartile [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/42\">",
"     42",
"    </a>",
"    ]. However, no difference between the LAS quartiles was noted in the charges for the first year, when the transplantation admission charges were excluded. Nonetheless, charges for lung transplantation in this study are lower than those reported in the 2008 Milliman Research Report [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/45\">",
"     45",
"    </a>",
"    ]. In this independent cost analysis of organ transplantation in the US, the mean charge for single lung transplantation was $256,600 compared with $344,700 for bilateral transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/45\">",
"     45",
"    </a>",
"    ]. It is difficult to reconcile the differences between these two reports as they represent different patient populations, transplant centers, and health care providers.",
"   </p>",
"   <p>",
"    A study from the United Kingdom reported that the mean cost of medical therapy for patients awaiting lung transplantation was $73,564 compared with $176,640 for single lung recipients and $180,528 for bilateral recipients over a 15 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/41\">",
"     41",
"    </a>",
"    ]. The costs per quality-adjusted life year gained were $48,241 for single lung recipients and $32,803 for bilateral recipients. The authors concluded that lowered medication costs and improved quality of life benefits would improve the cost-effectiveness of lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wage effects are not included in the cost-effectiveness analysis in most studies, and if recipients returned to work, this would be an obvious asset. Employment patterns did not change after transplantation in the only study that specifically addressed this issue, and only 38 percent of the recipients felt that they were able to work [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3480/abstract/19,36\">",
"     19,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, lung transplantation is an expensive treatment with perhaps only modest improvements in quality-adjusted survival. Nonetheless, there is no social consensus on the monetary value of a quality-adjusted life year gained through lung transplantation or any other treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19603?source=see_link\">",
"       \"Patient information: Lung transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of lung transplants performed each year has grown steadily since 1985, although further increases in this number appear to be limited by organ availability. The proportion of bilateral lung transplants has increased and surpassed that of single lung transplants (",
"      <a class=\"graphic graphic_figure graphicRef71574 \" href=\"UTD.htm?14/25/14736\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common diseases that lead to lung transplant, in order of frequency, are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, alpha-1 antitrypsin deficiency, and idiopathic pulmonary arterial hypertension (IPAH) (",
"      <a class=\"graphic graphic_figure graphicRef61485 \" href=\"UTD.htm?30/25/31135\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Responsibility for recipient evaluation, waiting list management, and matching of donor organs with recipients is shared by three organizations: United Network for Organ Sharing (UNOS), Organ Procurement Organizations (OPOs), and lung transplant centers. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Organizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung allocation to patients on the waiting list has been based on a \"Lung Allocation Score\" since May 2005. This score includes a measure urgency of need for transplant and a post transplant likelihood of survival measure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lung allocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary graft dysfunction (PGD) and infections are the major causes of death in the first year post transplant; chronic graft dysfunction due to bronchiolitis obliterans syndrome is the major cause of death after the first year. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcomes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36057?source=see_link\">",
"       \"Primary lung graft dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"       \"Infection in the solid organ transplant recipient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The underlying lung disease influences mortality post transplant: first year mortality is lowest for COPD and highest for IPAH. In contrast, mortality at 10 years is highest for COPD and IPF and lowest for cystic fibrosis and alpha-1 antitrypsin (",
"      <a class=\"graphic graphic_figure graphicRef57297 \" href=\"UTD.htm?38/5/38992\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung transplant is an expensive treatment that provides only modest gains in quality adjusted life years. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/1\">",
"      HARDY JD, WEBB WR, DALTON ML Jr, WALKER GR Jr. LUNG HOMOTRANSPLANTATION IN MAN. JAMA 1963; 186:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/2\">",
"      Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/3\">",
"      Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med 1986; 314:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/4\">",
"      Cooper JD, Patterson GA, Grossman R, Maurer J. Double-lung transplant for advanced chronic obstructive lung disease. Am Rev Respir Dis 1989; 139:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/5\">",
"      Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. J Heart Lung Transplant 2010; 29:1104.",
"     </a>",
"    </li>",
"    <li>",
"     Division of Transplantation, Bureau of Health Resources Development. 2005 Annual Report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network &mdash; Transplant Data:1995-2004. Health Resources and Services Administration; US Department of Health and Human Services, Rockville, MD 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/7\">",
"      Ware LB, Wang Y, Fang X, et al. Assessment of lungs rejected for transplantation and implications for donor selection. Lancet 2002; 360:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/8\">",
"      Ingemansson R, Eyjolfsson A, Mared L, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg 2009; 87:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/9\">",
"      Cypel M, Rubacha M, Yeung J, et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant 2009; 9:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/10\">",
"      Gries CJ, Mulligan MS, Edelman JD, et al. Lung allocation score for lung transplantation: impact on disease severity and survival. Chest 2007; 132:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/11\">",
"      McCurry KR, Shearon TH, Edwards LB, et al. Lung transplantation in the United States, 1998-2007. Am J Transplant 2009; 9:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/12\">",
"      Davis SQ, Garrity ER Jr. Organ allocation in lung transplant. Chest 2007; 132:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/13\">",
"      Iribarne A, Russo MJ, Davies RR, et al. Despite decreased wait-list times for lung transplantation, lung allocation scores continue to increase. Chest 2009; 135:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/14\">",
"      Yusen RD, Shearon TH, Qian Y, et al. Lung transplantation in the United States, 1999-2008. Am J Transplant 2010; 10:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/15\">",
"      Russo MJ, Iribarne A, Hong KN, et al. High lung allocation score is associated with increased morbidity and mortality following transplantation. Chest 2010; 137:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/16\">",
"      Meyer DM, Edwards LB, Torres F, et al. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg 2005; 79:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/17\">",
"      Titman A, Rogers CA, Bonser RS, et al. Disease-specific survival benefit of lung transplantation in adults: a national cohort study. Am J Transplant 2009; 9:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/18\">",
"      Liu V, Zamora MR, Dhillon GS, Weill D. Increasing lung allocation scores predict worsened survival among lung transplant recipients. Am J Transplant 2010; 10:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/19\">",
"      Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report--2005. J Heart Lung Transplant 2005; 24:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/20\">",
"      Christie JD, Sager JS, Kimmel SE, et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/21\">",
"      Thabut G, Vinatier I, Stern JB, et al. Primary graft failure following lung transplantation: predictive factors of mortality. Chest 2002; 121:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/22\">",
"      Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/23\">",
"      Prekker ME, Nath DS, Walker AR, et al. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2006; 25:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/24\">",
"      Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/25\">",
"      Huang HJ, Yusen RD, Meyers BF, et al. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant 2008; 8:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/26\">",
"      Meyers BF, de la Morena M, Sweet SC, et al. Primary graft dysfunction and other selected complications of lung transplantation: A single-center experience of 983 patients. J Thorac Cardiovasc Surg 2005; 129:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/27\">",
"      Sundaresan S, Trulock EP, Mohanakumar T, et al. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group. Ann Thorac Surg 1995; 60:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/28\">",
"      Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003; 22:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/29\">",
"      Valentine VG, Robbins RC, Berry GJ, et al. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant 1996; 15:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/30\">",
"      Lehto JT, Koskinen PK, Anttila VJ, et al. Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart-lung transplant recipients. Transpl Int 2005; 18:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/31\">",
"      Sol&eacute; A, Morant P, Salavert M, et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/32\">",
"      Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/33\">",
"      Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005; 24:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/34\">",
"      Amital A, Shitrit D, Raviv Y, et al. Development of malignancy following lung transplantation. Transplantation 2006; 81:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/35\">",
"      Ramsey SD, Patrick DL, Lewis S, et al. Improvement in quality of life after lung transplantation: a preliminary study. The University of Washington Medical Center Lung Transplant Study Group. J Heart Lung Transplant 1995; 14:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/36\">",
"      Gross CR, Savik K, Bolman RM 3rd, Hertz MI. Long-term health status and quality of life outcomes of lung transplant recipients. Chest 1995; 108:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/37\">",
"      Kugler C, Fischer S, Gottlieb J, et al. Health-related quality of life in two hundred-eighty lung transplant recipients. J Heart Lung Transplant 2005; 24:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/38\">",
"      Vasiliadis HM, Collet JP, Poirier C. Health-related quality-of-life determinants in lung transplantation. J Heart Lung Transplant 2006; 25:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/39\">",
"      van Den BERG JW, Geertsma A, van Der BIJ W, et al. Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life. Am J Respir Crit Care Med 2000; 161:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/40\">",
"      Ramsey SD, Patrick DL, Albert RK, et al. The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest 1995; 108:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/41\">",
"      Anyanwu AC, McGuire A, Rogers CA, Murday AJ. An economic evaluation of lung transplantation. J Thorac Cardiovasc Surg 2002; 123:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/42\">",
"      Arnaoutakis GJ, Allen JG, Merlo CA, et al. Impact of the lung allocation score on resource utilization after lung transplantation in the United States. J Heart Lung Transplant 2011; 30:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/43\">",
"      Vasiliadis HM, Collet JP, Penrod JR, et al. A cost-effectiveness and cost-utility study of lung transplantation. J Heart Lung Transplant 2005; 24:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3480/abstract/44\">",
"      Gartner SH, Sevick MA, Keenan RJ, Chen GJ. Cost-utility of lung transplantation: a pilot study. J Heart Lung Transplant 1997; 16:1129.",
"     </a>",
"    </li>",
"    <li>",
"     Hauboldt RH, Hanson SG, Bernstein GR: 2008 U.S. organ and tissue transplant cost estimates and discussion. file://publications.milliman.com/research/health-rr/pdfs/2008-us-organ-tisse-RR4-1-08.pdf (Accessed on February 01, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4659 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3480=[""].join("\n");
var outline_f3_25_3480=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      United Network for Organ Sharing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Organ Procurement Organizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lung transplant centers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LUNG ALLOCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Causes of death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cost and cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4659|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/25/14736\" title=\"figure 1\">",
"      Lung transplant procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/25/31135\" title=\"figure 2\">",
"      Indications for lung transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/5/38992\" title=\"figure 3\">",
"      Survival by diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4659|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/0/40972\" title=\"table 1\">",
"      Lung allocation score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=related_link\">",
"      Evaluation and treatment of acute lung transplant rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12425?source=related_link\">",
"      Lung transplantation: Deceased donor evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31192?source=related_link\">",
"      Lung transplantation: Disease-based choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5640?source=related_link\">",
"      Lung transplantation: Donor lung preservation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38697?source=related_link\">",
"      Lung transplantation: Procedure and postoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12233?source=related_link\">",
"      Noninfectious complications following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19603?source=related_link\">",
"      Patient information: Lung transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36057?source=related_link\">",
"      Primary lung graft dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_25_3481="Skull fractures in adults";
var content_f3_25_3481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Skull fractures in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3481/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3481/contributors\">",
"     William G Heegaard, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3481/contributors\">",
"     Michelle H Biros, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3481/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3481/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/25/3481/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/25/3481/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/25/3481/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skull fractures have plagued humankind throughout history [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/1\">",
"     1",
"    </a>",
"    ]. They occur when forces striking the head exceed the mechanical integrity of the calvarium. Significant skull fractures are often accompanied by moderate or severe intracranial injury and extracranial injuries associated with high-energy trauma, such as cervical and other spine fractures and thoracoabdominal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/2-9\">",
"     2-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, mechanisms, clinical presentation, associated complications, and initial management of skull fractures in adults are reviewed here. Skull fractures in children and intracranial injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link\">",
"     \"Skull fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=see_link\">",
"     \"Intracranial epidural hematoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38696?source=see_link\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of skull fractures among head injured adults who present to emergency departments (ED) is unknown. The parietal bone is most frequently fractured, followed by the temporal, occipital, and frontal bones [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/10\">",
"     10",
"    </a>",
"    ]. Linear fractures are the most common, followed by depressed and basilar skull fractures. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Definition and presentation of skull fracture types'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Much of the data on skull fractures in adults come from studies of traumatic brain injury (TBI). Each year, approximately 1.7 million people sustain head injuries in the United States (US) alone, with 1.3 million undergoing emergency evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to one retrospective study of 207 head-injured patients, 37 percent of those with associated intracranial pathology sustained a linear skull fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/12\">",
"     12",
"    </a>",
"    ]. According to another retrospective study of 2254 cases of head trauma from assault, approximately one-third sustained a skull fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common causes of head injury in adults include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Falls",
"     </li>",
"     <li>",
"      Assaults",
"     </li>",
"     <li>",
"      Motor vehicle collisions",
"     </li>",
"     <li>",
"      Penetrating missiles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although skull fractures themselves may or may not indicate the presence of significant TBI, certain skull fracture types, such as depressed skull fractures, basilar skull fractures with associated cerebral spinal fluid (CSF) leak, and fractures of the temporal-parietal bone that traverse the middle meningeal artery and vein, are associated with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/2-5,8,14,15\">",
"     2-5,8,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY AND MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skull is made up of the frontal, ethmoid, sphenoid, and occipital bones, two parietal bones, and two temporal bones (",
"    <a class=\"graphic graphic_figure graphicRef72739 \" href=\"UTD.htm?1/35/1592\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82226 \" href=\"UTD.htm?14/13/14552\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60967 \" href=\"UTD.htm?30/43/31416\">",
"     figure 3",
"    </a>",
"    ). The unique layered architecture of these bones enhances the skull's strength. Each bone consists of solid inner and outer layers, separated by a layer of cancellous bone (the diplo&euml;). In adults, the bones of the skull average between 2 and 6 mm in thickness; the bones in the temporal region are usually the thinnest and therefore at the greatest risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who sustain a fracture of the temporal bone are at high risk for extra-axial hematoma (ie, bleeding beneath the skull but outside the brain parenchyma). This is due to the temporal bone's relative weakness and the proximity of the middle meningeal artery and vein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=see_link\">",
"     \"Intracranial epidural hematoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fractures involving the frontal sinus are also considered high risk; they are frequently associated with contusions to the anterior portion of the frontal lobes and with dural tears. The thin cribriform plate is often shattered. Other high risk fractures include those over the transverse or sagittal sinus, due to the increased risk of major bleeding, and basilar skull fractures resulting in CSF otorrhea or rhinorrhea. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Basilar skull fracture'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Skull fractures occur from direct trauma to the head [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/18\">",
"     18",
"    </a>",
"    ]. The amount and dispersion of the kinetic energy involved primarily determine whether a skull fracture is linear or depressed. The smaller the area receiving the blow and the greater the energy delivered, the more likely that a depressed fracture will result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREHOSPITAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The priorities of prehospital trauma management remain unchanged in patients with skull fractures. These are discussed in detail separately. Special considerations in the patient with a skull fracture are described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prehospital personnel should assume a skull fracture exists in any patient who has sustained a significant head injury or other major trauma. High kinetic energy is needed to cause a skull fracture. Therefore, maintaining immobilization of the cervical and thoracic spine is of great importance.",
"   </p>",
"   <p>",
"    Open or closed skull fractures can be associated with large scalp lacerations with profuse bleeding that can be difficult to control. Initial management consists of steady direct pressure at the source of bleeding. A dressing held in place by a circumferential head bandage is often NOT sufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial assessment of any trauma patient is focused on the rapid identification and stabilization of life-threatening injuries. Patients with major head trauma may require airway protection. Bleeding from wounds associated with skull fractures can be profuse. Direct pressure is the initial treatment. Occasionally, large scalp lacerations require the placement of Raney Clips&reg;, which compress the scalp, thereby providing tamponade (",
"    <a class=\"graphic graphic_picture graphicRef52581 \" href=\"UTD.htm?11/10/11426\">",
"     picture 1",
"    </a>",
"    ). Alternatively, large sutures may be placed in the scalp to control bleeding. Commercial hemostatic agents (eg, QuikClot&reg;) are becoming more widely available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link\">",
"     \"Fibrin sealant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the primary trauma survey is performed and life-threatening issues are addressed, the emergency physician or trauma surgeon performs a secondary survey that may reveal findings suggestive of a skull fracture or intracranial injury. Such findings may include depressed mental status, focal cranial nerve or other neurologic deficits, scalp lacerations or contusions, bony step-off of the skull, or periorbital or retroauricular ecchymosis. Scalp wounds should NOT be probed. When examining potential skull fracture sites, the clinician should take care to avoid injury from bone edges or fragments.",
"   </p>",
"   <p>",
"    The blunt force required to cause a skull fracture is substantial. Therefore, it is essential to rule out underlying traumatic brain injury. The emergency department work-up of patients with suspected skull fractures, or deemed to be at significant risk for intracranial injury based upon clinical assessment, is primarily radiographic. Clinical assessment of the patient with a minor head injury, including decision rules for imaging, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncontrast CT scan (including bone windows) is the imaging modality of choice for patients with a suspected skull fracture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83506 \" href=\"UTD.htm?23/32/24070\">",
"     image 1",
"    </a>",
"    ). Although research on the subject is scant, multidetector computed tomography (MDCT) using thin slices and three dimensional reconstructions appears to enable identification of virtually all clinically significant skull fractures. Tissue windows simultaneously allow for the identification of parenchymal injury (eg, cerebral contusion) as well as other forms of intracranial hemorrhage (eg, subdural hematoma).",
"   </p>",
"   <p>",
"    MRI is useful when vascular or ligamentous injury is suspected, but should be considered an ancillary study to CT.",
"   </p>",
"   <p>",
"    Little evidence exists to guide the use of CT angiography or other types of angiography in the setting of skull fracture. If MDCT reveals findings suggestive of a basilar skull fracture involving the petrous portion of the temporal bone, it is reasonable to obtain CT angiography to assess for vascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/19\">",
"     19",
"    </a>",
"    ]. In one observational study, 13 of 71 patients with a basilar skull fracture sustained a cerebrovascular injury identified by angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/20\">",
"     20",
"    </a>",
"    ]. It is generally best to discuss the need for angiography with a radiologist to determine the best approach.",
"   </p>",
"   <p>",
"    Skull x-rays are of no benefit if a CT scan is to be performed. If CT is unavailable, skull radiographs using two views should be performed (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83505 \" href=\"UTD.htm?41/37/42578\">",
"     image 2",
"    </a>",
"    ). However, fractures, especially depressed skull fractures, may be difficult to see on plain radiographs. Tangential views of the skull may improve detection. A CT should be obtained if plain radiographs reveal a skull fracture, in order to determine the presence of an intracranial hemorrhage. Although negative plain x-rays in a low risk clinical setting (eg, minor mechanism, normal neurologic examination) are reassuring, they cannot rule out intracranial injury.",
"   </p>",
"   <p>",
"    Between 5 to 15 percent of patients with skull fractures also sustain cervical spine fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/5,21\">",
"     5,21",
"    </a>",
"    ]. A careful assessment for spinal and other concurrent injuries is essential. The circumstances of the injury and the patient's history and clinical presentation provide the basis for further diagnostic work-up. A toxicologic screen may be useful to assist in the assessment of a patient with altered mental status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DEFINITION AND PRESENTATION OF SKULL FRACTURE TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skull fractures can be categorized as linear, depressed, or basilar. In open skull fractures, lacerations of the scalp allow direct contact between the environment and the brain parenchyma, thereby increasing the risk of infection. In closed skull fractures, intact scalp tissue provides an effective barrier between the environment and the skull and brain tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Linear skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A linear skull fracture is a single fracture that most often extends through the entire thickness of the calvarium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83506 \" href=\"UTD.htm?23/32/24070\">",
"     image 1",
"    </a>",
"    ). They occur most often in the temporoparietal, frontal, and occipital regions.",
"   </p>",
"   <p>",
"    The great majority of linear skull fractures have minimal or no clinical significance. However, fractures that cross the middle meningeal groove in the temporal bone or major venous dural sinuses may disturb these vascular structures causing significant extra-axial bleeding (ie, bleeding beneath the skull but outside the brain parenchyma). Separation (ie, diastasis) of skull sutures can occur following trauma and most often involves the coronal or lambdoid sutures.",
"   </p>",
"   <p>",
"    Adults with simple, closed linear skull fractures usually present without neurologic symptoms. On examination, they may have swelling overlying the fracture site. The minority of patients who develop significant intracranial hemorrhage can present with depressed mental status, headache, vomiting, cranial nerve deficits, or other findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Depressed skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressed skull fractures occur when trauma of significant force drives a segment of the skull below the level of the adjacent skull (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51743 \" href=\"UTD.htm?4/17/4368\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59474 \" href=\"UTD.htm?38/11/39092\">",
"     image 4",
"    </a>",
"    ). These fractures often involve injury to the brain parenchyma and place patients at significant risk for central nervous system infection, seizures, and death if not identified early and managed appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. Mortality appears to be high among patients with depressed fractures who present with a significant decline in mental status [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/27\">",
"     27",
"    </a>",
"    ]. No large prospective epidemiological studies exist to determine the incidence of depressed skull fractures. Of 1075 patients evaluated for head trauma at one major trauma center, 63 were noted to have a depressed skull fracture sustained through a nonpenetrating mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depressed skull fractures may be closed or open. Closed (or simple) depressed fractures exist when no scalp laceration is present over or adjacent to the fracture. Open (or compound) depressed skull fractures exist when a scalp laceration lies over or adjacent to the fracture site. The majority of depressed skull fractures are open, and clinicians should assume that any depressed skull fracture is open until it is proven otherwise [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of underlying brain injury determines the clinical presentation of patients with depressed skull fractures. About 25 percent of patients sustain at least a brief loss of consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/29\">",
"     29",
"    </a>",
"    ]. Wounds that may be associated with a depressed skull fracture should be inspected, and the external region around such wounds may be carefully palpated (although the usefulness of palpation is often limited due to swelling). However, the wound itself should NOT be blindly probed.",
"   </p>",
"   <p>",
"    The force necessary to create a depressed skull fracture is significant and results from direct trauma from an object, such as a bat or club onto a small area [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/10,25,26,30,31\">",
"     10,25,26,30,31",
"    </a>",
"    ]. Such mechanisms of injury can dislodge bone fragments or result in a portion of the skull becoming lodged beneath another segment. Bone fragments and the edges of depressed skull segments can easily lacerate the adjacent dura mater, creating a portal of entry into the cerebral spinal fluid (CSF), thereby increasing the risk of CNS infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Basilar skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basilar skull fractures involve at least one of the five bones that comprise the base of the skull: cribriform plate of the ethmoid bone, orbital plate of the frontal bone, petrous and squamous portion of the temporal bone, and the sphenoid and occipital bones [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Basilar skull fractures occur most commonly through the temporal bone and thus, are at high risk for extra-axial hematomas, particularly epidural hematomas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50231 \" href=\"UTD.htm?24/37/25169\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71123 \" href=\"UTD.htm?22/58/23471\">",
"     image 6",
"    </a>",
"    ). This is due to the temporal bone's relative weakness and the proximity of the middle meningeal artery and vein.",
"   </p>",
"   <p>",
"    Basilar skull fractures can cause a dural tear, creating a communication between the subarachnoid space, the paranasal sinuses, and the middle ear. CSF leaks develop in approximately 11 to 45 percent of basilar skull fractures according to retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. These leaks can develop within one or up to several days following injury and may manifest as otorrhea or rhinorrhea, which are considered pathognomonic for a basilar skull fracture. Most traumatic CSF leaks resolve spontaneously within seven days, but in rare instances they can persist for as long as several months.",
"   </p>",
"   <p>",
"    The degree of underlying brain tissue and cranial nerve injury determines the neurologic presentation. Patients often develop nausea and vomiting due to the proximity of the brainstem centers involved in stimulating nausea and managing vestibular function. Oculomotor deficits from injuries to cranial nerves III, IV, or VI can occur, as may facial nerve palsies or hearing loss from injury to cranial nerves VII and VIII, respectively.",
"   </p>",
"   <p>",
"    Clinical signs can often be used to diagnose basilar skull fractures and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retroauricular or mastoid ecchymosis (ie, Battle sign) typically appears one to three days after the fracture is sustained (",
"      <a class=\"graphic graphic_picture graphicRef69660 \" href=\"UTD.htm?39/39/40561\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Raccoon eyes\" is a common term for periorbital ecchymosis, which suggests a basilar skull fracture or anterior or middle fossa facial trauma (",
"      <a class=\"graphic graphic_picture graphicRef68268 \" href=\"UTD.htm?9/38/9827\">",
"       picture 3",
"      </a>",
"      ). Like Battle sign, raccoon eyes are typically NOT present during the examination immediately following the injury but appear one to three days later.",
"     </li>",
"     <li>",
"      Clear rhinorrhea or otorrhea is found in up to 20 percent of temporal bone fractures. Such leaks may be detected within hours or up to several days after trauma.",
"     </li>",
"     <li>",
"      Hemotympanum is blood behind the tympanic membrane. It is a common finding in basilar skull fractures that involve the petrous ridge of the temporal bone and generally appears within hours of injury [",
"      <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/30\">",
"       30",
"      </a>",
"      ]. Hemotympanum is detected by otoscopy, which reveals the blue to purple hue taken on by the tympanic membrane (",
"      <a class=\"graphic graphic_picture graphicRef75382 \" href=\"UTD.htm?5/6/5216\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to research performed to validate the Canadian Head CT rule, the signs of basilar skull fracture (ie, Battle sign, raccoon eyes, hemotympanum,",
"    <span class=\"nowrap\">",
"     otorrhea/rhinorrhea)",
"    </span>",
"    are collectively highly predictive of a clinically important head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/35\">",
"     35",
"    </a>",
"    ]. Smaller observational studies confirm the high predictive value of these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are reports of tympanic membrane perforation in association with temporal and basilar skull fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/38\">",
"     38",
"    </a>",
"    ]. Direct bleeding from the ear&nbsp;may occur in this situation. Any patient who is assessed to be at high risk for a temporal bone or basilar skull fracture and has bleeding from his ear should undergo a CT scan of the head with thin cuts in the region of the temporal and basilar skull.",
"   </p>",
"   <p>",
"    A rare but significant complication of a basilar skull fracture is traumatic carotid cavernous fistula (TCCF). According to a retrospective review, the overall incidence of TCCF in basilar skull fractures is 3.8 percent, with middle fossa basilar skull fractures having the highest association [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/39\">",
"     39",
"    </a>",
"    ]. Other examples of uncommon injuries sustained by the carotid artery that may occur following basilar skull fractures, particularly those involving the carotid canal, include thrombosis and dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Penetrating skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating injuries of the skull occur as a result of gunshot wounds, stab wounds, and blast injuries. They generally involve significant brain injury and intracranial hemorrhage. Emergent neurosurgical consultation is needed to determine management.",
"   </p>",
"   <p>",
"    Tangential skull fractures warrant special mention. They are caused by an impact that occurs at an oblique angle to the skull. In one study, 24 percent of patients with tangential gunshot wounds (GSW) to the head sustained intracranial hemorrhage, while 16 percent had skull fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/42\">",
"     42",
"    </a>",
"    ]. Any patient with a tangential GSW to the scalp should undergo CT scanning of the head because of this high association with intracranial injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SPECIFIC INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Linear fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific intervention is necessary for linear skull fractures if a noncontrast CT scan reveals no underlying brain injury. Emergent neurosurgical consultation is obtained for patients with intracranial hemorrhage (ICH) associated with a linear skull fracture.",
"   </p>",
"   <p>",
"    Patients are admitted for observation if there is any suspicion or clinical evidence of brain injury. The goal of observation is to detect any worsening of neurologic function as a delayed complication of ICH. Such findings usually appear within 24 hours of injury. Patients with linear skull fractures and evidence of ICH on CT should be observed in facilities with neurosurgery.",
"   </p>",
"   <p>",
"    Patients with linear skull fractures but no evidence on CT of ICH should be observed in the emergency department (ED) for four to six hours prior to discharge to detect delayed complications of trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/5\">",
"     5",
"    </a>",
"    ]. If the patient is neurologically intact and there are no significant extracranial injuries, the patient may then be discharged, provided there is adequate supervision at home for the subsequent 24 hours. Clear discharge instructions must be provided, including instructions to return to the ED immediately should symptoms suggestive of intracranial injury (eg, headache, vomiting, lethargy) develop.",
"   </p>",
"   <p>",
"    Adult patients with simple linear skull fractures do not require long term follow-up unless they also demonstrate concussive symptoms or other evidence of mild traumatic brain injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Depressed fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with depressed skull fractures are at increased risk of infection and seizures, and prophylactic measures are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tetanus status should be determined if possible and prophylaxis given as appropriate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link&amp;anchor=H7#H7\">",
"       \"Tetanus-diphtheria toxoid vaccination in adults\", section on 'Immunization for patients with injuries'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that prophylactic antibiotics be given for five to seven days to prevent the risk of subsequent CNS infection, although data supporting this approach is scant [",
"      <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/44\">",
"       44",
"      </a>",
"      ]. Suggested antibiotics are identical to those for penetrating head trauma. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Penetrating injuries'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Anticonvulsants are often given to reduce the risk of seizures, despite a dearth of supporting evidence [",
"      <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/10,29\">",
"       10,29",
"      </a>",
"      ]. The initiation of such therapy and drug selection should be performed in consultation with a neurosurgeon or neurologist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4935?source=see_link\">",
"       \"Post-traumatic seizures and epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with depressed skull fractures are admitted to neurosurgery, and this service should be consulted as soon as the injury is recognized.",
"   </p>",
"   <p>",
"    The Brain Trauma Foundation suggests that open skull fractures depressed more than the thickness of the cranium be treated with elevation in the operating room; many neurosurgeons elect to elevate any fracture depressed greater than 5 mm below the adjacent inner table [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/26\">",
"     26",
"    </a>",
"    ]. Emergent elevation is generally recommended if there is a dural tear, pneumocephalus, an underlying hematoma, or a grossly contaminated wound [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/45\">",
"     45",
"    </a>",
"    ]. Most skull fractures that are depressed more than 1 cm are managed with early surgery to reduce the risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, open, depressed skull fractures without evidence of dural penetration or significant complications (eg, intracranial hematoma, severe wound contamination, frontal sinus involvement) on CT may be managed nonoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/26\">",
"     26",
"    </a>",
"    ]. Uncomplicated, closed, depressed skull fractures may also be managed nonoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Basilar fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial hemorrhage caused by a basilar skull fracture frequently represents a surgical emergency and requires immediate neurosurgical consultation. All patients with basilar skull fractures require admission for observation, regardless of the need for surgical intervention.",
"   </p>",
"   <p>",
"    Basilar skull fractures can produce a dural tear, which can cause a cerebral spinal fluid (CSF) leak. Clinically, this is suggested by the presence of clear or blood-tinged rhinorrhea or otorrhea in a head-injured patient. If the fluid is blood tinged, the \"halo\" sign (also called the \"ring\" or \"target\" sign) may be useful to determine the presence of CSF. To perform the test, a drop of the fluid is placed on a tissue or filter paper. A rapidly expanding ring of clear fluid around red blood defines a positive test. Of note, the halo test does",
"    <strong>",
"     NOT",
"    </strong>",
"    differentiate among CSF, saline, saliva, and other clear fluids and has not been formally studied in a clinical setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H10#H10\">",
"     \"Facial trauma in adults\", section on 'Examination of specific body parts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CSF can be distinguished from local nasal secretions more accurately by the presence of beta-trace protein, which is found in high concentrations in CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/27,34,36\">",
"     27,34,36",
"    </a>",
"    ], or beta-2 transferrin, which is found only in CSF, perilymph, and aqueous humor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/26\">",
"     26",
"    </a>",
"    ]. The availability of both beta-trace proteins and beta-2 transferrin laboratory techniques may be limited in many hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of CSF leaks resolve spontaneously within one week of injury and without CNS complications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. A systematic review and meta-analysis of five randomized trials and 17 other studies (involving over 2000 patients) of antibiotic prophylaxis following basilar skull fracture concluded that routine prophylaxis is not supported by the available evidence, but noted that this evidence contains methodological shortcomings and is therefore not conclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/47\">",
"     47",
"    </a>",
"    ]. We generally do not give prophylactic antibiotics initially for basilar skull fractures, unless the patient is at increased risk (eg, immunocompromised). The incidence of bacterial meningitis rises substantially if the leak persists past seven days and we suggest that prophylactic antibiotics be given in such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/49\">",
"     49",
"    </a>",
"    ]. Antibiotic selection is identical to that for penetrating head trauma. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Penetrating injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cranial nerve palsies are a delayed complication of basilar skull fractures. They generally present two to three days following injury and are due to nerve compression or contusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. These palsies may respond to treatment with glucocorticoids, although no large clinical trials have been performed to support this approach. Common treatment regimens are similar to those used for nontraumatic palsies (eg, Bell's palsy). We suggest starting such treatment in consultation with otolaryngology or neurosurgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=see_link\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Facial nerve palsies that appear acutely in association with basilar skull fractures are due to nerve transections. These injuries do NOT respond to glucocorticoid therapy and carry a poor prognosis for recovery of nerve function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anticoagulated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies of patients taking anticoagulants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) who sustain minor head trauma without a skull fracture suggest such patients are at high risk of intracranial hemorrhage (ICH) and that signs of neurologic deterioration may not appear for up to six hours following injury [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Therefore, patients taking anticoagulants and who sustain head trauma of sufficient force to cause a skull fracture, particularly a basilar skull fracture, are at even greater risk for ICH. Such risk may be greatest among elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/25/3481/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that all patients who are anticoagulated and have sustained a skull fracture be admitted to a facility with neurosurgery for a minimum of 24 hours of observation. Patients should be admitted to a hospital unit capable of performing hourly neurologic reassessments for a minimum of six hours. Thereafter, neurologic reassessment can be performed every two to four hours for the remainder of the observation period. An emergent head CT should be obtained if any sign of neurologic deterioration develops.",
"   </p>",
"   <p>",
"    Reversal of excess coagulation from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or newer anticoagulants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H32#H32\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Emergency treatment of bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients at greater risk of bleeding from causes other than anticoagulants also require extreme caution and are managed in a similar fashion. The management of patients with hemophilia who have sustained head trauma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H33#H33\">",
"     \"Treatment of hemophilia\", section on 'Severe hemorrhage and head trauma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Penetrating injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skull fractures sustained from penetrating trauma are considered open and patients are treated with IV antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"      piperacillin",
"     </a>",
"     /tazobactam.",
"    </span>",
"    Immediate neurosurgical consultation is needed for all patients with potentially survivable injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;No large randomized trials looking at the management of isolated skull fractures have been performed. Outcome generally depends upon the severity of the underlying brain injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=see_link\">",
"     \"Intracranial epidural hematoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38696?source=see_link\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=see_link\">",
"       \"Patient information: Skull and facial fractures (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical findings suggestive of a skull fracture or intracranial injury following trauma include: depressed mental status, focal cranial nerve or other neurologic deficits, scalp lacerations or contusions, bony step-off of the skull, periorbital or retroauricular ecchymosis, headache, and nausea and vomiting. Scalp wounds should",
"      <strong>",
"       NOT",
"      </strong>",
"      be probed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The blunt force required to cause a skull fracture is substantial. Therefore, it is essential to rule out underlying traumatic brain injury. Multidetector computed tomography (MDCT) using thin slices and three dimensional reconstructions enables identification of clinically significant skull fractures and intracranial hemorrhage. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The great majority of isolated linear skull fractures have no clinical significance. Fractures that cross the middle meningeal groove in the temporal bone or major venous dural sinuses may cause significant extra-axial bleeding. Adults with simple, closed linear skull fractures usually present without neurologic symptoms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Linear skull fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific intervention is necessary for linear skull fractures if a noncontrast CT scan reveals no underlying brain injury. Such patients can be discharged after four to six hours of observation, assuming the absence of neurologic findings and significant noncranial injuries. Emergent neurosurgical consultation is obtained for patients with intracranial hemorrhage (ICH) associated with a linear skull fracture. Patients are admitted for observation if there is any suspicion or clinical evidence of brain injury. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Linear fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depressed skull fractures occur when trauma of significant force drives a segment of the skull below the level of the adjacent skull. These fractures often involve injury to the brain parenchyma and place patients at significant risk for central nervous system infection, seizures, and death. The majority of depressed skull fractures are open. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Depressed skull fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with depressed skull fractures are admitted to a neurosurgery service. They should receive tetanus prophylaxis as appropriate. We suggest they also be treated with prophylactic antibiotics for five to seven days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Suggested antibiotics are identical to those used for penetrating head trauma. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Penetrating injuries'",
"      </a>",
"      above.) Anticonvulsants are sometimes given and treatment should be initiated in consultation with neurosurgery. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Depressed fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Basilar skull fractures occur most commonly through the temporal bone and patients with such fractures are at high risk for ICH. Clinical signs commonly used to diagnose basilar skull fractures include retroauricular or mastoid ecchymosis, periorbital ecchymosis, CSF rhinorrhea or otorrhea, and hemotympanum. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Basilar skull fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergent neurosurgical consultation should be obtained for any ICH associated with a basilar skull fracture. All patients with basilar skull fractures require admission for observation. Complications may include CSF leak and cranial nerve injury. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Basilar fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients who are taking anticoagulants and have sustained a skull fracture are at high risk for ICH and should be admitted for observation to a facility with neurosurgery, regardless of the absence of hemorrhage on initial CT imaging. Patients should be admitted to a hospital unit capable of performing hourly neurologic reassessments. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Anticoagulated patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1739089\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hippocratic Writings, Lloyd G.  (Ed), Penguin Group, London 1978.",
"    </li>",
"    <li>",
"     Britt PM, Heiseman JE. Imaging evaluation. In: Head Injury, 4th, Cooper PR, Golfinos JG.  (Eds), McGraw-Hill, New York 2000. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/3\">",
"      Chan KH, Mann KS, Yue CP, et al. The significance of skull fracture in acute traumatic intracranial hematomas in adolescents: a prospective study. J Neurosurg 1990; 72:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/4\">",
"      Hung CC, Chiu WT, Lee LS, et al. Risk factors predicting surgically significant intracranial hematomas in patients with head injuries. J Formos Med Assoc 1996; 95:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/5\">",
"      Macpherson BC, MacPherson P, Jennett B. CT evidence of intracranial contusion and haematoma in relation to the presence, site and type of skull fracture. Clin Radiol 1990; 42:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/6\">",
"      Hsiao KY, Hsiao CT, Weng HH, et al. Factors predicting mortality in victims of blunt trauma brain injury in emergency department settings. Emerg Med J 2008; 25:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/7\">",
"      Butcher I, McHugh GS, Lu J, et al. Prognostic value of cause of injury in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/8\">",
"      Carson HJ. Brain trauma in head injuries presenting with and without concurrent skull fractures. J Forensic Leg Med 2009; 16:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/9\">",
"      Mu&ntilde;oz-S&aacute;nchez MA, Murillo-Cabezas F, Cayuela-Dom&iacute;nguez A, et al. Skull fracture, with or without clinical signs, in mTBI is an independent risk marker for neurosurgically relevant intracranial lesion: a cohort study. Brain Inj 2009; 23:39.",
"     </a>",
"    </li>",
"    <li>",
"     Golfinos JG, Cooper PR. Skull fracture and post-traumatic cerebrospinal fluid fistula. In: Head Injury, 4th, Cooper PR, Golfinos JG.  (Eds), McGraw-Hill, New York 2000. p.155.",
"    </li>",
"    <li>",
"     Faul M XL, Wald MM, Coronado VG. Traumatic brain injury in the United States: Emergency department visits, hospitalizations, and deaths 2002-2006. In: Centers for Disease Control and Prevention, AG, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 2010. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/12\">",
"      Cooper PR, Ho V. Role of emergency skull x-ray films in the evaluation of the head-injured patient: a retrospective study. Neurosurgery 1983; 13:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/13\">",
"      Jiang JY, Feng H, Fu Z, et al. Violent head trauma in China: report of 2254 cases. Surg Neurol 2007; 68 Suppl 2:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/14\">",
"      Poon WS, Rehman SU, Poon CY, Li AK. Traumatic extradural hematoma of delayed onset is not a rarity. Neurosurgery 1992; 30:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/15\">",
"      Fabbri A, Servadei F, Marchesini G, et al. Early predictors of unfavourable outcome in subjects with moderate head injury in the emergency department. J Neurol Neurosurg Psychiatry 2008; 79:567.",
"     </a>",
"    </li>",
"    <li>",
"     Carpenter MB. Gross anatomy of the brain. In: Core Text of Neuroanatomy, 4th, Williams &amp; Wilkins, Baltimore 1991. p.23.",
"    </li>",
"    <li>",
"     Rockswold GL. Head Injury. In: Emergency Medicine: A Comprehensive Study Guide, 4th, Tintinalli JE.  (Ed), McGraw-Hill, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/18\">",
"      GURDJIAN ES, WEBSTER JE, LISSNER HR. Studies on skull fracture with particular reference to engineering factors. Am J Surg 1949; 78:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/19\">",
"      Ahmed KA, Alison D, Whatley WS, Chandra RK. The role of angiography in managing patients with temporal bone fractures: a retrospective study of 64 cases. Ear Nose Throat J 2009; 88:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/20\">",
"      Ringer AJ, Matern E, Parikh S, Levine NB. Screening for blunt cerebrovascular injury: selection criteria for use of angiography. J Neurosurg 2010; 112:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/21\">",
"      Mulligan RP, Mahabir RC. The prevalence of cervical spine injury, head injury, or both with isolated and multiple craniomaxillofacial fractures. Plast Reconstr Surg 2010; 126:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/22\">",
"      Braakman R. Survey and follow-up of 225 consecutive patients with a depressed skull fracture. J Neurol Neurosurg Psychiatry 1971; 34:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/23\">",
"      Braakman R. Depressed skull fracture: data, treatment, and follow-up in 225 consecutive cases. J Neurol Neurosurg Psychiatry 1972; 35:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/24\">",
"      Harris JH Jr. High yield criteria and skull radiography. JACEP 1979; 8:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/25\">",
"      Jennett B, Miller JD. Infection after depressed fracture of skull. Implications for management of nonmissile injuries. J Neurosurg 1972; 36:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/26\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of depressed cranial fractures. Neurosurgery 2006; 58:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/27\">",
"      Kaptigau WM, Ke L, Rosenfeld JV. Open depressed and penetrating skull fractures in Port Moresby General Hospital from 2003 to 2005. P N G Med J 2007; 50:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/28\">",
"      Heary RF, Hunt CD, Krieger AJ, et al. Nonsurgical treatment of compound depressed skull fractures. J Trauma 1993; 35:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/29\">",
"      Chesnut RM. Care of central nervous system injuries. Surg Clin North Am 2007; 87:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/30\">",
"      Hasso AN, Ledington JA. Traumatic injuries of the temporal bone. Otolaryngol Clin North Am 1988; 21:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/31\">",
"      Dahiya R, Keller JD, Litofsky NS, et al. Temporal bone fractures: otic capsule sparing versus otic capsule violating clinical and radiographic considerations. J Trauma 1999; 47:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/32\">",
"      Nosan DK, Benecke JE Jr, Murr AH. Current perspective on temporal bone trauma. Otolaryngol Head Neck Surg 1997; 117:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/33\">",
"      Yilmazlar S, Arslan E, Kocaeli H, et al. Cerebrospinal fluid leakage complicating skull base fractures: analysis of 81 cases. Neurosurg Rev 2006; 29:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/34\">",
"      Tubbs, RS, Shoja, MM, Loukas, M. William Henry Battle and Battle's sign: mastoid ecchymosis as an indicator of basilar skull fracture. J Neurosurg 2009; :.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/35\">",
"      Stiell IG, Clement CM, Rowe BH, et al. Comparison of the Canadian CT Head Rule and the New Orleans Criteria in patients with minor head injury. JAMA 2005; 294:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/36\">",
"      Pretto Flores L, De Almeida CS, Casulari LA. Positive predictive values of selected clinical signs associated with skull base fractures. J Neurosurg Sci 2000; 44:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/37\">",
"      Savastio G, Golfieri R, Pastore Trossello M, Venturoli L. [Cranial trauma: the predictability of the presentation symptoms as a screening for radiologic study]. Radiol Med 1991; 82:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/38\">",
"      Pulec JL, Deguine C. Temporal bone fracture with tympanic membrane perforation and hemorrhage. Ear Nose Throat J 2003; 82:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/39\">",
"      Liang W, Xiaofeng Y, Weiguo L, et al. Traumatic carotid cavernous fistula accompanying basilar skull fracture: a study on the incidence of traumatic carotid cavernous fistula in the patients with basilar skull fracture and the prognostic analysis about traumatic carotid cavernous fistula. J Trauma 2007; 63:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/40\">",
"      York G, Barboriak D, Petrella J, et al. Association of internal carotid artery injury with carotid canal fractures in patients with head trauma. AJR Am J Roentgenol 2005; 184:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/41\">",
"      Resnick DK, Subach BR, Marion DW. The significance of carotid canal involvement in basilar cranial fracture. Neurosurgery 1997; 40:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/42\">",
"      Anglin D, Hutson HR, Luftman J, et al. Intracranial hemorrhage associated with tangential gunshot wounds to the head. Acad Emerg Med 1998; 5:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/43\">",
"      Al-Haddad SA, Kirollos R. A 5-year study of the outcome of surgically treated depressed skull fractures. Ann R Coll Surg Engl 2002; 84:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/44\">",
"      Ali B, Ghosh A. Antibiotics in compound depressed skull fractures. Emerg Med J 2002; 19:552.",
"     </a>",
"    </li>",
"    <li>",
"     Qureshi NH, Harsh GR. Skull fractures. eMEDICINE, 2001. file://emedicine.medscape.com/article/248108-overview (Accessed on June 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/46\">",
"      Michel O, Bamborschke S, Nekic M, Bachmann G. Beta-trace protein (prostaglandin D synthase)--a stable and reliable protein in perilymph. Ger Med Sci 2005; 3:Doc04.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/47\">",
"      Ratilal BO, Costa J, Sampaio C, Pappamikail L. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev 2011; :CD004884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/48\">",
"      Santos SF, Rodrigues F, Dias A, et al. [Post-traumatic meningitis in children: eleven years' analysis]. Acta Med Port 2011; 24:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/49\">",
"      Brodie HA, Thompson TC. Management of complications from 820 temporal bone fractures. Am J Otol 1997; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/50\">",
"      Adegbite AB, Khan MI, Tan L. Predicting recovery of facial nerve function following injury from a basilar skull fracture. J Neurosurg 1991; 75:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/51\">",
"      Maiman DJ, Cusick JF, Anderson AJ, Larson SJ. Nonoperative management of traumatic facial nerve palsy. J Trauma 1985; 25:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/52\">",
"      Reynolds FD, Dietz PA, Higgins D, Whitaker TS. Time to deterioration of the elderly, anticoagulated, minor head injury patient who presents without evidence of neurologic abnormality. J Trauma 2003; 54:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/53\">",
"      Mina AA, Knipfer JF, Park DY, et al. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J Trauma 2002; 53:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/54\">",
"      Cohen DB, Rinker C, Wilberger JE. Traumatic brain injury in anticoagulated patients. J Trauma 2006; 60:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/55\">",
"      Karni A, Holtzman R, Bass T, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg 2001; 67:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/25/3481/abstract/56\">",
"      Franko J, Kish KJ, O'Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma 2006; 61:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 344 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3481=[""].join("\n");
var outline_f3_25_3481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY AND MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREHOSPITAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DEFINITION AND PRESENTATION OF SKULL FRACTURE TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Linear skull fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Depressed skull fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Basilar skull fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Penetrating skull fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT OF SPECIFIC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Linear fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Depressed fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Basilar fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anticoagulated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Penetrating injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1739089\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/344\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/344|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/32/24070\" title=\"diagnostic image 1\">",
"      Skull fracture CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/37/42578\" title=\"diagnostic image 2\">",
"      Linear skull fracture x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/17/4368\" title=\"diagnostic image 3\">",
"      CT of depressed skull fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/11/39092\" title=\"diagnostic image 4\">",
"      Radiographs of depressed skull fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/37/25169\" title=\"diagnostic image 5\">",
"      CT of temporal skull fracture with epidural blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/58/23471\" title=\"diagnostic image 6\">",
"      CT of temporal skull fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/344|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/35/1592\" title=\"figure 1\">",
"      Lateral skull anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/13/14552\" title=\"figure 2\">",
"      Anterior skull anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/43/31416\" title=\"figure 3\">",
"      Inferior skull anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/344|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/10/11426\" title=\"picture 1\">",
"      Raney clip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/39/40561\" title=\"picture 2\">",
"      Battles sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/38/9827\" title=\"picture 3\">",
"      Raccoon eyes 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/6/5216\" title=\"picture 4\">",
"      Hemotympanum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=related_link\">",
"      Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=related_link\">",
"      Evaluation and acute management of cervical spinal column injuries in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=related_link\">",
"      Facial trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=related_link\">",
"      Intracranial epidural hematoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38696?source=related_link\">",
"      Nonaneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=related_link\">",
"      Patient information: Skull and facial fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4935?source=related_link\">",
"      Post-traumatic seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=related_link\">",
"      Skull fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=related_link\">",
"      Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_25_3482="Saquinavir: Drug information";
var content_f3_25_3482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Saquinavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/34/21029?source=see_link\">",
"    see \"Saquinavir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37177?source=see_link\">",
"    see \"Saquinavir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Invirase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Invirase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     ECG should be done prior to starting therapy; do not initiate therapy if pretreatment QT interval &gt;450 msec. Saquinavir should always be used with concomitant ritonavir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral: 1000 mg twice daily given in combination with ritonavir 100 mg twice daily. This combination should be given together and within 2 hours after a full meal in combination with a nucleoside analog.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustments when administered in combination therapy:",
"     </b>",
"     Saquinavir: 1000 mg twice daily administered with lopinavir 400 mg/ritonavir 100 mg (Kaletra&trade;) twice daily; no additional ritonavir is necessary",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F219669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37177?source=see_link\">",
"      see \"Saquinavir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral: Children &gt;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical studies did not include sufficient numbers of patients &ge;65 years of age. Use caution due to increased frequency of organ dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Invirase&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Invirase&reg;: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10916632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229206.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229206.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F219626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer saquinavir and ritonavir at the same time and within 2 hours after a full meal. Patients unable to swallow capsules may open capsules and mix contents with 15 mL of syrup (or sorbitol if diabetic or glucose intolerant) or with 3 teaspoons of jam. Mixture should be stirred for 30-60 seconds and then administered entirely. Suspension should be at room temperature prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F219624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection; used in combination with ritonavir and other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Saquinavir may be confused with SINEquan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F219685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Incidence data shown for saquinavir soft gel capsule formulation (no longer available) in combination with ritonavir.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     10%: Gastrointestinal: Nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (6%), fever (3%), anxiety, depression, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (3%), rash (3%), dry lips/skin (2%), eczema (2%), verruca",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Lipodystrophy (5%), hyperglycemia (3%), hypoglycemia, hyperkalemia, libido disorder, serum amylase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (8%), vomiting (7%), abdominal pain (6%), constipation (2%), abdominal discomfort, appetite decreased, buccal mucosa ulceration, dyspepsia, flatulence, taste alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased, ALT increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (2%), CPK increased, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine kinase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonia (5%), bronchitis (3%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Incidence not currently defined (limited to significant reactions; reported for hard or soft gel capsule with/without ritonavir)",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Cyanosis, heart valve disorder (including murmur), hyper-/hypotension, peripheral vasoconstriction, prolonged QT interval, prolonged PR interval, syncope, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Agitation, amnesia, ataxia, confusion, hallucination, hyper-/hyporeflexia, myelopolyradiculoneuritis, neuropathies, poliomyelitis, progressive multifocal encephalopathy, psychosis, seizures, somnolence, speech disorder, suicide attempt",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Alopecia, bullous eruption, dermatitis, erythema, maculopapular rash, photosensitivity, Stevens-Johnson syndrome, skin ulceration, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, diabetes, electrolyte changes, TSH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Ascites, colic, dysphagia, esophagitis, bloody stools, gastritis, intestinal obstruction, hemorrhage (rectal), pancreatitis, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: impotence, prostate enlarged, hematuria, UTI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic; Acute myeloblastic leukemia, anemia (including hemolytic), leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, GGT increased, hepatitis, hepatomegaly, hepatosplenomegaly, jaundice, liver disease exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blepharitis, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Otic: Otitis, hearing decreased, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Nephrolithiasis, renal calculus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Dyspnea, hemoptysis, pharyngitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Immune reconstitution syndrome, infections (bacterial, fungal, viral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: AV block (second or third degree), torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F219629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to saquinavir or any component of the formulation; congenital or acquired QT prolongation, refractory hypokalemia or hypomagnesemia, concomitant use of other medications that both increase saquinavir plasma concentrations and prolong the QT interval; complete AV block (without implanted ventricular pacemaker) or patients at high risk of complete AV block; severe hepatic impairment; coadministration of saquinavir/ritonavir with alfuzosin, amiodarone, bepridil, cisapride, dofetilide, ergot derivatives, flecainide, lidocaine (systemic), lovastatin, midazolam (oral), pimozide, propafenone, quinidine, rifampin, sildenafil (when used for pulmonary artery hypertension [eg, Revatio&reg;]),simvastatin, trazodone, or triazolam",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Concurrent use with procainamide, sotalol, astemizole, or terfenadine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F219613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Saquinavir/ritonavir prolongs the QT interval, potentially leading to torsade de pointes, and prolongs the PR interval, potentially leading to heart block. Second- or third-degree AV block has been reported (rare). An ECG should be performed for all patients prior to starting saquinavir/ritonavir therapy; do not initiate therapy in patients with a baseline QT interval &gt;450 msec or diagnosed with long QT syndrome.  If baseline QT interval &lt;450 msec, may initiate therapy but a subsequent ECG is recommended after ~3-4 days of therapy. If subsequent QT interval is &gt;480 msec or is prolonged over baseline by &gt;20 msec, therapy should be discontinued. Patients who may be at increased risk for QT- or PR-interval prolongation include those with heart failure, bradyarrhythmias, hepatic impairment, electrolyte abnormalities, ischemic heart disease, cardiomyopathy, structural heart disease, or those with pre-existing cardiac conduction abnormalities; ECG monitoring is recommended for these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased cholesterol: Increases in total cholesterol and triglycerides have been reported; screening should be done prior to therapy and periodically throughout treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalances: Correct electrolyte abnormalities prior to treatment and monitor potassium and magnesium levels during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding during protease inhibitor therapy has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: May cause hepatitis and/or exacerbate pre-existing hepatic dysfunction; use with caution in patients with underlying mild-to-moderate hepatic disease, including hepatitis B or C, cirrhosis, or chronic alcoholism; contraindicated in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Formulation contains lactose; Canadian product labeling recommends against use in patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: must be used in combination with ritonavir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cross-resistance to other HIV drugs: Continued administration after loss of viral suppression efficacy may increase the likelihood of cross-resistance to other protease inhibitors. Promptly discontinue therapy if viral suppression response is lost.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F219681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: May enhance the arrhythmogenic effect of Saquinavir. Saquinavir may increase the serum concentration of Bepridil [Off Market].",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adult patients taking saquinavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting saquinavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clorazepate: Saquinavir may increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Saquinavir may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Saquinavir may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Saquinavir may enhance the arrhythmogenic effect of Dofetilide. Saquinavir may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: Saquinavir may enhance the adverse/toxic effect of Efavirenz. Efavirenz may decrease the serum concentration of Saquinavir.  Management: When used together with efavirenz, saquinavir should not be used as the sole protease inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir). Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Saquinavir may enhance the arrhythmogenic effect of Flecainide. Saquinavir may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flurazepam: Saquinavir may increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving saquinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Ketoconazole (Systemic). Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving saquinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Saquinavir may enhance the arrhythmogenic effect of Lidocaine (Systemic). Saquinavir may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Saquinavir may decrease the serum concentration of Pravastatin. This effect has only been demonstrated with saquinavir/ritonavir. The individual contributions of saquinavir and ritonavir are unknown.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Saquinavir may enhance the arrhythmogenic effect of Propafenone. Saquinavir may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Saquinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Saquinavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May enhance the adverse/toxic effect of Saquinavir. Specifically, the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Saquinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Saquinavir may enhance the QTc-prolonging effect of TraZODone. Saquinavir may increase the serum concentration of TraZODone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Saquinavir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F219643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: A high-fat meal maximizes bioavailability. Saquinavir levels may increase if taken with grapefruit juice. Management: Administer within 2 hours of a full meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Saquinavir serum concentrations may be decreased by St John's wort and garlic capsules. Management: Avoid St John's wort. Avoid garlic supplementation.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F219633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Saquinavir crosses the human placenta in minimal amounts. Based on limited data, saquinavir administered twice daily with ritonavir 100 mg twice daily provide adequate levels in pregnant women. The DHHS Perinatal HIV Guidelines consider saquinavir and ritonavir to be an alternative combination for use during pregnancy; use without ritonavir is",
"     <b>",
"      not",
"     </b>",
"     recommended. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and  protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F219657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F219634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F219635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take within 2 hours of a meal. Invirase&reg; capsules and tablets contain lactose (not expected to induce symptoms of intolerance).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F219632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Invirase Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (270): $1097.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Invirase Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (120): $1121.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F219621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor ECG (prior to therapy and after 3-4 days of therapy); serum potassium and magnesium levels, triglycerides and cholesterol (prior to initiation and periodically during therapy); viral load, CD4 count; glucose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F219636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fortovase (AR, BG, CN, IN, MX, PE, UY, VE);",
"     </li>",
"     <li>",
"      Invirase (AT, AU, BB, BE, BF, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CZ, DE, DK, EC, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, IE, IL, IT, JM, KE, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F219612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F219628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor; increased with high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 700 L; does not distribute into CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: ~98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Invirase&reg;: ~4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (81% to 88%), urine (1% to 3%) within 5 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Collier AC, Coombs RW, DA, et al, &ldquo;Treatment of Human Immunodeficiency Virus Infection With Saquinavir, Zidovudine, and Zalcitabine,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(16):1011-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/8598838/pubmed\" id=\"8598838\" target=\"_blank\">",
"        8598838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deeks SG, Smith M, Holodniy M, et al, &ldquo;HIV-1 Protease Inhibitors. A Review for Clinicians,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(2):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/8990341/pubmed\" id=\"8990341\" target=\"_blank\">",
"        8990341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilts AE and Fish DN, &ldquo;Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55:2528-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9853641/pubmed\" id=\"9853641\" target=\"_blank\">",
"        9853641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsu A, Granneman GR, Cao G, et al, &ldquo;Pharmacokinetic Interactions Between Two Human Immunodeficiency Virus Protease Inhibitors, Ritonavir and Saquinavir,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1998, 63(4):453-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9585800/pubmed\" id=\"9585800\" target=\"_blank\">",
"        9585800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kakuda TN, Struble KA, and Piscitelli SC, &ldquo;Protease Inhibitors for the Treatment of Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55(3):233-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9492254/pubmed\" id=\"9492254\" target=\"_blank\">",
"        9492254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman MB and Simionatto C, &ldquo;A Review of Protease Inhibitor-Induced Hyperglycemia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(1):114-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9917085/pubmed\" id=\"9917085\" target=\"_blank\">",
"        9917085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaul DR, Cinti SK, Carver PL, et al, &ldquo;HIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complications,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(3):281-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/10221367/pubmed\" id=\"10221367\" target=\"_blank\">",
"        10221367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDonald CK and Kuritzkes DR, &ldquo;Human Immunodeficiency Virus Type 1 Protease Inhibitors,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1997, 157(9):951-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9140265/pubmed\" id=\"9140265\" target=\"_blank\">",
"        9140265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mueller BU, &ldquo;Antiviral Chemotherapy,&rdquo;",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 1997, 9(2):178-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9204247/pubmed\" id=\"9204247\" target=\"_blank\">",
"        9204247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Noble S and Faulds D, &ldquo;Saquinavir: A Review of Its Pharmacology and Clinical Potential in the Management of HIV Infection,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 52(1):93-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/8799687/pubmed\" id=\"8799687\" target=\"_blank\">",
"        8799687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry CM and Noble S, &ldquo;Saquinavir Soft-Gel Capsule Formulation. A Review of Its Use in Patients With HIV Infection,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 55(3):461-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9530549/pubmed\" id=\"9530549\" target=\"_blank\">",
"        9530549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rana KZ and Dudley MN, &ldquo;Human Immunodeficiency Virus Protease Inhibitors,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(1):35-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9917077/pubmed\" id=\"9917077\" target=\"_blank\">",
"        9917077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rhone SA, Hogg RS, Yip B, et al, &ldquo;The Antiviral Effect of Ritonavir and Saquinavir in Combination Amongst HIV-Infected Adults: Results From a Community-Based Study,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1998, 12(6):619-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9583602/pubmed\" id=\"9583602\" target=\"_blank\">",
"        9583602",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh M, Arora R, and Jawad E, &ldquo;HIV Protease Inhibitors Induced Prolongation of the QT Interval: Electrophysiology and Clinical Implications,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2010, 17(6):e193-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/19636247/pubmed\" id=\"19636247\" target=\"_blank\">",
"        19636247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vella S and Floridia M, &ldquo;Saquinavir. Clinical Pharmacology and Efficacy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1998, 34(3):189-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/25/3482/abstract-text/9533981/pubmed\" id=\"9533981\" target=\"_blank\">",
"        9533981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9877 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3482=[""].join("\n");
var outline_f3_25_3482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219647\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219648\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219687\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219652\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219669\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219653\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219623\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219609\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10916632\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219626\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219624\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219694\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219685\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219629\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219613\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219681\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219617\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219643\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219619\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219633\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219657\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219634\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219635\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219632\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219621\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219636\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219612\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219628\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9877|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/34/21029?source=related_link\">",
"      Saquinavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37177?source=related_link\">",
"      Saquinavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_25_3483="Features SIRS";
var content_f3_25_3483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Defining features of systemic inflammatory response syndrome (SIRS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Two or more of the following conditions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temperature &gt;38.5&deg;C or &lt;35.0&deg;C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart rate of &gt;90 beats/minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory rate of &gt;20 breaths/minute or PaCO",
"        <sub>",
"         2",
"        </sub>",
"        of &lt;32 mm Hg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        WBC count of &gt;12,000 cells/mL, &lt;4000 cells/mL, or &gt;10 percent immature (band) forms",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WBC count: white blood cell count.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Annane, D, Bellissant, E, Cavaillon, JM. Septic shock. Lancet 2005; 365:63.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3483=[""].join("\n");
var outline_f3_25_3483=null;
var title_f3_25_3484="Risk aggressive behavior GIST";
var content_f3_25_3484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed approach for defining risk of aggressive behavior in gastrointestinal stromal tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Size*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mitotic count&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very low",
"risk",
"       </td>",
"       <td>",
"        &lt;2 cm",
"       </td>",
"       <td>",
"        &lt;5 per 50 HPF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low risk",
"       </td>",
"       <td>",
"        2-5 cm",
"       </td>",
"       <td>",
"        &lt;5 per 50 HPF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Intermediate",
"risk",
"       </td>",
"       <td>",
"        &lt;5 cm",
"       </td>",
"       <td>",
"        6-10 per 50 HPF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-10 cm",
"       </td>",
"       <td>",
"        &lt;5 per 50 HPF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        High risk",
"       </td>",
"       <td>",
"        &gt;5 cm",
"       </td>",
"       <td>",
"        &gt;5 per 50 HPF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10 cm",
"       </td>",
"       <td>",
"        Any mitotic rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any size",
"       </td>",
"       <td>",
"        &gt;10 per 50",
"HPF",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HPF: high powered fields.",
"     <br>",
"      * Size represents the single largest dimension. Admittedly this may vary somewhat before and after fixation and between observers. There is a general but poorly defined sense that perhaps the size threshold for aggressive behaviour should be 1-2 cm less in the small bowel than elsewhere.",
"      <br>",
"       &bull; Ideally mitotic count should be standardized according to surface area examined (based on size of high power fields), but there are no agreed definitions in this regard. Despite inevitable subjectivity in recognition of mitoses and variability in the area of high power fields, such mitotic counts still prove useful.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher, CD, Berman, JJ, Corless, C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Int J Surg Pathol 2002; 10:81. Copyright &copy;2002 Westminster Publications.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3484=[""].join("\n");
var outline_f3_25_3484=null;
var title_f3_25_3485="Clin features vomiting children";
var content_f3_25_3485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible implications of some signs and symptoms associated with vomiting in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Contents of vomitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Undigested: achalasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bilious: postampullary obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Blood or \"coffee ground\": gastritis, ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bloody after forceful vomiting: Mallory-Weiss tear",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malodorous: stasis with bacterial overgrowth",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Feculent: obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Force of vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Effortless, regurgitation: gastroesophageal reflux, rumination syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Projectile: pyloric stenosis, obstruction, cyclic vomiting syndrome,&nbsp;metabolic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Food associations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Triggered by cow's milk, soy, gluten: protein intolerance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple food exacerbants: eosinophilic gastroenteritis, fructose intolerance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Periodicity of vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paroxysmal, cyclic: cyclic vomiting syndrome, porphyria, carcinoid, pheochromocytoma, familial dysautonomia.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Headache, vertigo, visual changes: metabolic, toxin, CNS disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fundoscopic evidence of increased ICP: CNS mass",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other symptoms and signs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lack of nausea: CNS mass",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Esophageal pain: esophagitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diarrhea: infectious enteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Abdominal peristalsis: obstruction, pyloric stenosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peritoneal signs: surgical abdomen, perforated appendicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Jaundice: hepatobilary etiology or urinary tract infection in a neonate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Surgical scars: obstruction secondary to adhesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Early morning vomiting: pregnancy, CNS mass",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vomiting with meals: peptic ulcer disease, psychogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disproportionate hypotension, hyperkalemia: adrenal crisis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system. ICP: intracranial pressure.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Verma R. Vomiting. In: Clinical Pediatric Gastroenterology. Altschuler SM, Liacouras CA (Eds),Churchill Livingstone, Philadephia 1998. p.105.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3485=[""].join("\n");
var outline_f3_25_3485=null;
var title_f3_25_3486="Cicatricial alopecias";
var content_f3_25_3486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F88347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F88347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cicatricial (scarring) alopecias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epidemiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features on scalp",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-scalp involvement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Lymphocytic primary cicatricial alopecias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discoid lupus erythematosus",
"       </td>",
"       <td>",
"        Onset usually in young adulthood; more common in women than men; may occur independently or in patients with SLE",
"       </td>",
"       <td>",
"        Erythematous, atrophic plaques with follicular plugging, hyperpigmentation, and/or hypopigmentation",
"       </td>",
"       <td>",
"        Face, ears, and other sites may be affected; a minority of cases are associated with systemic lupus erythematosus",
"       </td>",
"       <td>",
"        Interface dermatitis, epidermal atrophy, follicular plugging, basement membrane thickening, perifollicular superficial and deep lymphoplasmacytic infiltrate; DIF shows IgG, IgM, and C3 at the BMZ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lichen planopilaris",
"       </td>",
"       <td>",
"        Most common in Caucasian and East Indian women",
"       </td>",
"       <td>",
"        Areas of scarring surrounded by follicles with erythema and scale; itching and pain may be severe",
"       </td>",
"       <td>",
"        May be accompanied by cutaneous, nail, or mucous membrane lichen planus",
"       </td>",
"       <td>",
"        Lichenoid infiltrate around the isthmus and infundibulum, interface dermatitis, concentric lamellar fibroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frontal fibrosing alopecia",
"       </td>",
"       <td>",
"        Mostly post-menopausal women",
"       </td>",
"       <td>",
"        Perifollicular erythema, follicular hyperkeratosis, band-like frontal alopecia",
"       </td>",
"       <td>",
"        Loss of eyebrows common",
"       </td>",
"       <td>",
"        Lichenoid infiltrate around the isthmus and infundibulum, apoptotic keratinocytes in outer root sheath, concentric lamellar fibroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Classic pseudopelade of Brocq",
"       </td>",
"       <td>",
"        Most common in middle-aged women",
"       </td>",
"       <td>",
"        Skin-colored scarred plaques resembling \"footprints in the snow\"",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Lymphocytic infiltrate around infundibulum, concentric lamellar fibroplasia around follicles in later lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central centrifugal cicatricial alopecia",
"       </td>",
"       <td>",
"        Most common in women of African origin",
"       </td>",
"       <td>",
"        Patch of scarring alopecia on crown of scalp that progresses centrifugally",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Premature desquamation of the inner root sheath, loss of sebaceous glands, variable perifollicular chronic inflammation at isthmus and infundibulum, concentric lamellar fibroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alopecia mucinosa",
"       </td>",
"       <td>",
"        May be associated with mycosis fungoides or CTCL",
"       </td>",
"       <td>",
"        Erythematous or skin-colored indurated plaques with alopecia, follicular papules",
"       </td>",
"       <td>",
"        Eyebrow involvement may be present",
"       </td>",
"       <td>",
"        Mucin deposits in outer root sheath, eventual replacement of follicles by mucin, lymphocytic infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Keratosis folliculars spinulosa decalvans",
"       </td>",
"       <td>",
"        X-linked inheritance of mutation in the MBTPS2 gene; less commonly autosomal dominant transmission",
"       </td>",
"       <td>",
"        Noninflammatory, hyperkeratotic follicular papules and progressive hair loss",
"       </td>",
"       <td>",
"        Eyebrow and eyelash involvement may be present, photophobia",
"       </td>",
"       <td>",
"        Follicular plugging and hypergranulosis, primarily lymphocytic perifollicular infiltrate, fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Neutrophilic primary cicatricial alopecias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dissecting folliculitis",
"       </td>",
"       <td>",
"        Most common in young black men",
"       </td>",
"       <td>",
"        Inflammatory papules, pustules, fluctuant nodules, abscesses; may also have keloidal scarring",
"       </td>",
"       <td>",
"        May be associated with hidradenitis suppurativa and acne conglobata",
"       </td>",
"       <td>",
"        Follicular occlusion, intrafollicular and perifollicular neutrophilic infiltrate; follicular perforation, abscesses and sinus tracts in later stages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Folliculitis decalvans",
"       </td>",
"       <td>",
"        Most common in young and middle aged adults, particularly men",
"       </td>",
"       <td>",
"        Patches of alopecia, erythematous follicular papules, pustules, follicular hyperkeratosis, tufted folliculitis",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Interfollicular and perifollicular neutrophilic infiltrate; mixed infiltrate, granulomas, and fibrosis in later lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Mixed primary cicatricial alopecias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acne keloidalis nuchae",
"       </td>",
"       <td>",
"        Most common in young black men",
"       </td>",
"       <td>",
"        Dome-shaped papules and pustules on the occipital scalp and nape of the neck; keloids may develop",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Neutrophilic or lymphocytic inflammatory infiltrate around the isthmus and infundibulum; granulomatous infiltrate may also be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acne necrotica",
"       </td>",
"       <td>",
"        Usually occurs in adults",
"       </td>",
"       <td>",
"        Umbilicated, pruritic, painful papules that undergo central necrosis and resolve with varioliform scars",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Infundibular folliculitis with necrosis, lymphocytic or mixed inflammatory infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erosive pustular dermatosis of the scalp",
"       </td>",
"       <td>",
"        Most common in the elderly, particularly women",
"       </td>",
"       <td>",
"        Pustules, erosions, and crusted plaques",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Nonspecific early findings; older lesions with a chronic mixed inflammatory infiltrate and fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tinea capitis",
"       </td>",
"       <td>",
"        Usually affects children",
"       </td>",
"       <td>",
"        Scaly patches or plaques; kerion may develop",
"       </td>",
"       <td>",
"        Tinea corporis may be present",
"       </td>",
"       <td>",
"        Perifollicular inflammation and fungal elements within or around the hair shaft",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CTCL: cutaneous T-cell lymphoma; SLE: systemic lupus erythematosus; DIF: direct immunofluorescence; BMZ: basement membrane zone; SLE: systemic lupus erythematosus.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Otberg N, Shapiro J. Hair growth disorders. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill 2012.",
"      </li>",
"      <li>",
"       Childs JM, Sperling LC. Histopathology of scarring and nonscarring hair loss. Dermatol Clin 2013; 31:43.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3486=[""].join("\n");
var outline_f3_25_3486=null;
var title_f3_25_3487="TEE mitral valve vegetations";
var content_f3_25_3487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiogram (TEE) showing vegetations on the mitral valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 175px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bulky vegetations on the mitral valve as seen on transesophageal echocardiography in the four-chamber view transverse plane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_25_3487=[""].join("\n");
var outline_f3_25_3487=null;
